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ABSTRACT 
Neuronal cells are among the most morphologically elaborate cells in the human body.  The 
creation, maintenance and modification of such high complexity are dependent on the organization 
of neuronal cytoskeleton elements. Microtubules play an essential role in this regard, thanks to their 
ability to form a resistant and yet plastic cytoskeleton. The acquisition of a more rigid or a more 
dynamic configuration depends upon the coordination of a large number of regulatory proteins. 
The present work is on a poorly characterized but translationally promising family of such 
regulatory proteins called microtubule-severing proteins. The work focuses on two such proteins 
in two different scenarios: fidgetin in neurodevelopment and spastin in neurodegeneration. 
Fidgetin was found to play a unique role in neurodevelopment by targeting the dynamic domain of 
the axonal microtubule as opposed to its stable domain, with fidgetin thus behaving as a 
microtubule plasticity suppressor. Its inhibition was found to boost the dynamic microtubule mass 
of the axon, thereby enhancing neuroplastic characteristics such as axon growth and the number of 
processes extended by an individual neuron. This profound effect on dynamic microtubules has 
interesting translational implications in neuropathology: from treating the injured central nervous 
system to better understanding neurodevelopmental disorders such as autism. 
On the other side of the spectrum, there is spastin, mutations of which cause a selective slow 
degeneration of first order neurons from the cortico-spinal tracts. The prevailing idea of this 
neurodegeneration is that neurotoxic effect of mutated spastin occurs through a loss-of-function 
mechanism. The present study challenges this concept by demonstrating the existence of an 
alternative gain-of-function mechanism of action. The data suggest that mutated spastin could 
induce neurodegeneration by aberrantly activating kinases, in particular casein kinase II, which in 
turn, compromises vital neuronal processes such as intracellular transport. Continuation of the work 
will open the door to a completely new translational paradigm to find an efficient treatment to this 
incurable condition.    
 
  
  
  
BACKGROUND AND LITERATURE SURVEY 
Under the functional point of view, the nervous system can be considered as an exquisitely complex 
network in which information continuously circulates and modifies, allowing its rapid adaptation 
to the ever-changing external environment. This network is composed by the organized, selective 
connectivity between the functional elements, the neurons, whose function is not only to transmit 
signals from one point to another, but also to integrate, enrich or selectively remove information 
that will ultimate result in a change of a functionality of the target recipient cells [1]. The response 
that the nervous system can generate in correspondence to a specific stimulus can be very complex. 
This requires the activation of a selected subset of neurons in a very narrow, and at the same time, 
very precise spatial–temporal window. In order to express this complex function, every element of 
this network must respond adequately at every given time, conversely, the alteration of such 
function would result in pathological dysfunction of one or more process [1]. 
Neurons are extremely specialized cells that during the evolution perfected their capability to 
receive, integrate and ultimately transmit neuronal signals from one cell to another to carry growing 
information along the neural network [2]. In order to do this, the neuronal cells specialize different 
parts to a specific function [2-4]. Structures called dendrites are responsible for receiving 
information from other cells. At the cell body level, information is gathered and integrated, 
eventually to be transmitted toward the next cell target through another specialized structure called 
the axon. Considering the tight bond between the function and the structure, the neuronal 
morphology plays an essential role in the physiology of the entire nervous system. Cytoskeletal 
elements, such as actin filaments and microtubules play a pivotal role to keep this morphological-
functional connection working [5, 6]. In this work I will particularly focus on microtubules and 
how the regulation of this cytoskeleton component has strong implication in the neuronal 
functionality during physiological processes such as neurodevelopment and during 
neuropathological events such as neurodegeneration. 
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Microtubule cytoskeleton is particularly important for the neuronal functionality because its 
capability to form a stable cellular structure that is resistant to physical stimulation is extremely 
important [7]. However, considering the intrinsic dynamic nature of microtubules, this solid, stable 
cytoskeleton is everything but static, it continuously go tomoves in the event of microscopic 
rearrangement, allowing the cells the possibility to easily readapt its shape whenever it is needed. 
These opposing properties are even more important in neurons in which the continuous 
environmental changes demand a plastic, malleable morphology. But the contribution of 
microtubules on neuronal cell physiology is far to be just restricted on structural organizer of 
neuronal cell shape. Microtubules participate in the neuronal functionality in several different 
aspects: by creating preferential tracks for intracellular transport [8, 9]; by setting up intracellular 
signals for specific organelle distribution [10]; by generating intracellular forces and act as 
signaling devices [6]. The overlap of one or more of these intracellular processes make the 
phenomenon such as neuronal migration possible [6, 11], neuronal polarization/differentiation [12], 
maintenance of neuronal connectivity and finally, rearrangement of synaptic contact with neuronal 
plasticity [13]. The ultimate goal of all these processes is to locate each single neuron in the nervous 
system in the right position and make it capable to be a functional network component, a 
phenomenon that simply would not be possible without the presence of a responsive microtubule 
cytoskeleton. 
Evidences of the importance of microtubule cytoskeleton in neuronal physiology can be 
appreciated by taking a look on the correlation between altered microtubule regulation and 
neuropathology, from both neurodevelopmental disorders to neurodegenerative diseases [14-16]. 
Interestingly, considering the essential role of microtubule generally in the overall cell physiology 
(inside and outside the central nervous system), very limited number of pathologies can be directly 
connected to alterations occurring on the tubulin protein (so called tubulinopathies) [17, 18]. These 
apparent two can explain discrepancy major reasons: first the tubulin gene during the process of 
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speciation and evolution sustained several events of duplications, which gene product was 
conserved as microtubule elements. The presence of multiple functionally analogous genes makes 
the impact of a single gene mutation much less detrimental, and less prone to induce pathological 
consequences [18]. A second reason is the nature of mutation: in all the tubulinopathies the 
mutation causes minor changes of the tubulin structures, indicating that major alterations on tubulin 
function is simply incompatible with the most basic cellular processes, hence with life [18]. Many 
of the alterations pertaining to the microtubule cytoskeleton and neuronal functionality are instead 
the result of dysregulation on microtubule associated proteins (MAPs) [19-23], regulatory proteins 
(such as microtubule-severing proteins) or motor protein moving along microtubule and its 
regulators, and enzyme regulating microtubule post-translation modification (PTMs)  such as 
acetylation [24]. 
Microtubules 
Microtubules are the largest cytoskeleton structure in the cell. The basic constituents are the tubulin 
heterodimers, subunits composed by the constitutive association of α tubulin and β tubulin, forming 
a stable structural subunit [18]. The polarized assembly of these heterodimers (head to toe), forms 
a still polarized ultra-structural unit called a protofilament. Further assembly of protofilaments by 
using lateral interactions, creates a hollow, still polarized structure called microtubules. 
Maintenance of polarity has important biological consequence in many aspects of the microtubule 
physiology. The most important implication is the dynamic character of the two extremes (called 
tips) from each microtubule, in which the extreme subunit, α-tubulin, is much less dynamic , and 
for this reason called the minus tip, whereas the other extreme subunit, GTP-β tubulin, results in a 
more rapid turnover and for this reason is called the plus tip [25, 26].   In many cell types 
microtubules are specifically organized and ordered to maintain their polarity orientation 
coherently toward the same direction. Neurons is a classical example, where a specialized cellular 
compartment such as the axon has almost all the microtubules oriented with the plus-end facing the 
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axon tip and the minus-end facing the cell body [2, 27]. This very uniform polarization allows the 
fine regulation of important processes such as the unidirectional, vectorial transport of specific 
cellular organelles such as vesicles. Indeed, the two major molecular motor proteins responsible 
for organelles transport along the axon, Kinesin-1 for the anterograde transport and Dynein for the 
retrograde one, can perform the unidirectional transport so efficiently as a result of the 
homogeneous polarity of microtubule in the axon [2]. 
Microtubules continuously undergo to event of disassembly (called catastrophe) and re-assembly 
(called rescue) [28] allowing for the formation of a cytoskeleton that has a great degree of plasticity 
and at the same time conferring a strong structural support [7]. The fine-tuning of the 
polymerization versus depolymerization process can make the entire microtubule cytoskeleton 
more plastic or more stable. The regulation of these properties depend on the selective activation 
of a large series of microtubule- regulatory proteins, discussed later, generally called as 
microtubule- associated proteins (MAP). However, the processes of polymerization and 
depolymerization are directly determined by the biophysical properties of the tubulin subunits [26].  
Each tubulin polypeptide can be divided functionally and structurally into three domains: the N-
terminal domain, the intermediate domain and the C-terminal domain. The N-terminal domain is 
responsible for GTP binding, and slightly differs between α tubulin and β tubulin, where the 
binding site in the α tubulin is structurally more rigid, impairing the GTP hydrolysis capability. 
Because of this the binding site of the α subunit is called the N-site (not exchangeable site). The β-
polypeptide instead has a GTP binding site more flexible, and hence competent for a fast GTP 
hydrolysis (E-site). The differences on this domain make a substantial difference between the 
strong intra-dimer interactions and the much weaker inter-dimer interactions, accounting for the 
disassembly of the microtubule polymer, the heterodimers remain the undividable elements. The 
intermediate loop is instead responsible for lateral proto-filament interactions. Finally, the C-
terminal domain contains the C-terminal tail which is the hotspot for all the PTMs on microtubules, 
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except for acetylation.  This region, conversely from the other part of the tubulin protein, is 
unstructured and does not participate in any tubulin-tubulin interaction on the structure. Not 
surprisingly, the different α and  β isoforms diverge the most on this region, indicating the 
possibility of a differential mechanism of regulation between the different tubulin isotypes[29, 30]. 
Tubulin diversity I: tubulin isotypes 
 A remarkable characteristic of all the tubulin isoforms across the species, is the highly conserved 
tridimensional structure, composed by a compact globular body and a relatively unstructured C-
terminal tail. The highly conserved tridimensional structure does not correlate with a high degree 
of similarity in their primary sequence: indeed, across the species all the tubulins have primary 
sequence homology no greater than 40% [18, 30]. Strikingly, within the same species several 
different tubulin isotypes exists and each one has subtle, but probably biological relevant 
differences in their primary sequence.  Great part of the differences between the tubulin isotypes 
lay along the high variable C-terminal tail on both α and β tubulin, indicating that this region is 
minimally involved in the critical regions for microtubule polymerization [18, 30]. Instead, that is 
the site where the majority of microtubule PTMs occur. In mammals, at least 9 α and 9 β tubulin 
isotypes exist [31]. The expression of each isotype can be tissue specific examples are the βIII/ βII  
tubulin in nervous tissue where βIII is almost exclusively neuronal [32], and βI in the marginal 
band on platelets [33, 34]) or developmentally regulated. The reason of this divergence in the 
primary sequence is not completely understood. In the past it has been proposed that the difference 
of primary sequence could reflect a difference in function from each isotype. But the discovery of 
the capability from all the different tubulin isotypes to a freely formed “mixed” tubulin polymer, 
disproves in great part this theory [35]. In reality from all the different isoforms just a few tubulin 
isotypes may play a unique cell-specific function. A classic example is βI tubulin, that is expressed 
in platelets and is responsible for the formation and contraction of the marginal band, is an essential 
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process for the dramatic morphological changes occurring during the activation of these cells [33, 
34]. 
Another example more relevant to this dissertation is the (almost) neuro-specific βIII tubulin, 
expressed only in neurons  of the central nervous system, and outside from that,  some other 
locations such as Sertoli cells and sperm cells [36], vestibular organ [37], nasal and colon 
epithelia[38]. In the brain, about one quarter of the overall tubulin is the βIII isotype. Considering 
the absence of βIII in glia, the relative amount of this tubulin isotype in neurons easily exceeds the 
25% [39]. In vitro experiments have shown that this isoform of tubulin has a significant increase 
of dynamicity compared to the other isoform [40]. This higher dynamic behavior is particularly 
suitable for a young microtubule cytoskeleton of newly developing neurons where, phenomena like 
neuronal migration, cell division, axon extension and pathfinding require a particularly dynamic 
cytoskeleton. However, the higher dynamicity is just a part of the specific βIII function.  Mature 
nervous system, composed by neurons with a required less dynamic cytoskeleton has about the 
same amount of βIII tubulin, making the question of its function at adult age puzzling, especially 
because during maturation the increased expression of microtubule stabilizing MAPs, such as 
MAP2 and Tau, is significantly increased [41, 42].  Another specific function of this isotype relies 
on its primary sequence: differently from any other tubulin, βIII isotype does not have a key 
cysteine residue in position 239 [43]. The presence of a serine instead of chemically more reactive 
cysteine, makes this tubulin isotype resistant to oxidative stress environments, typically present in 
nervous tissue. Indeed, any other tubulin isotype bearing in 239 position a cysteine residue are 
particularly sensitive to oxidation, and under oxidative stress the cysteine residue form an intra-
molecular disulfide bridge that is incompatible with microtubule assembly. Moreover the presence 
of other cysteines in unusual positions (such as position 124, 127 and 129) in the βIII protein could 
help the clearance in the cytosol of reactive oxygen species without compromise the microtubule 
cytoskeleton[31]. 
7 
 
 
Tubulin diversity II: tubulin post-translational modifications 
Considering the large number of functions that microtubules perform at the same time in varying 
regions of the cells, an intriguing question is how does the cell use a particular subset of 
microtubules for a specific function, meanwhile using others for a different function. One partial 
answer could be the selective expression of specific tubulin isotypes as I previously illustrated. 
However, considering the high capability of different tubulin isotypes to copolymerize, the 
diversity of tubulin in the primary sequence remains a partial answer to the problem [35]. Another 
possibility is to create transient, differential, domains or interactive surface on microtubule in 
correspondence to a particular cellular event.  Under the biological point of view, this domain can 
be created by PTMs [18, 44]. Indeed, microtubules are one of the most post-translationally modified 
structures in the entire cell. The PTMs occurring on microtubules can cause very different 
biochemical effects on the microtubule surface: some profoundly increase the total electrostatic 
charge (phosphorylation, poly/mono-glutamylation, poly-amination); others conversely can reduce 
it (for example, in the case of acetylation) [45]. However, the variety of PTMs does not stop on the 
change in electrostatic charge: proteolytic cleavage can alter the tubulin polypeptide irreversibly, 
like in the case of ∆3-tubulin [44]. In any case, all the modifications thus far have per se a limited 
or even nonexistent effect on processes related to microtubule polymerization. The numerous past 
in vitro studies and the elegant new in vivo approaches suggest that all these modifications have a 
profound effect on microtubules and its related function in virtue of their capability to recruit, 
activate or inhibit secondary effectors. In other words, microtubule PTMs may alter the capability 
of MAPs to bind/interact, altering microtubule related functions. Despite decades of dedicated work 
in the microtubule PTMs field, a lot of progress is still necessary to have a clear understanding as 
to what  the function of this alteration is and what is the foundation of the so called Tubulin Code 
hypothesis [44]. 
8 
 
 
For the purpose of this dissertation I will describe briefly the current idea of the best studied 
microtubules PTMs, giving a major emphasis to the acetylation, the PTM that has the greatest 
relevance from the work that I am going to illustrate. 
Tubulin Acetylation 
Tubulin is the most common acetylated substrate in the cytoplasm [46]. A growing number of PTM 
study\ies show that microtubules can be acetylated in different sites [47]. However due to the early 
nature of this discovery very little is known about the function of these modifications. Acetylation 
on α-tubulin at lysine 40 is the exception. This specific PTM  has been studied since the middle 
80`s [48] and several pieces of information can be extracted from this work, which has allowed us 
to have a better understanding of the complexity of the microtubule PTM world [44]. The 
acetylation on tubulin can be performed by several enzymes: ELP3, NAT10, ARD1, GCN5 just to 
mention a few [45]. However to date the major tubulin acetylase is considered α-TAT1 (α-tubulin 
acetyl transferase, MEC17 is the C. elegans ortholog) since the depletion of this protein causes the 
complete ablation of acetylation (on α-tubulin K60), meanwhile the depletion of the other tubulin 
acetylases causes only a partial effect on this PTM [49]. A clear interpretation of the biological 
function of this PTM to date  is still challenging, but a series of experiments indicate the potential 
correlation, in a context dependent scenario, between acetylation and microtubule stability. This 
idea arises from a series of very elegant experiments performed in the 80s. First when a microtubule 
preparation was incubated with destabilizing agents such as nocodazole or colchicine, the 
acetylated fraction of microtubule localized in the more stable fraction [50, 51]. Conversely, 
treatment with taxol, which make microtubules resistant to strong  microtubule-destabilizing agents 
such as cold or CaCl2, caused a net increase of microtubule  acetylation [16]. In a second set of 
studies, biotinylated brain tubulin was microinjected in human fibroblasts and the relative amount 
of newly incorporated tubulin was measured shortly after injection (1 hr.).  In this experiment 
almost all the non-acetylated tubulin was biotinylated (corresponding to the fraction of 
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microtubules recently incorporated, hence labile), meanwhile only the 50% of the acetylated 
tubulin was biotinylated, indicating that the turnover of acetylation was much slower, indicating 
that PTM occurs in tubulin subunits polymerized in stable, longed lived microtubule [52, 53]. These 
two experiments and many others since that time demonstrated that acetylation was a consequence 
of microtubule stabilization.  The slow catalytic activity of α-TAT1 merged with it required 
introduction and slow diffusion in the luminal space of microtubules, is in agreement with the 
reduced possibility of the enzyme to target newly assembled tubulin subunits [54].  
The acetylation is a PTM on microtubules that pose several challenging question,  starting from the 
enzymatic activity. The enzymatic acetylation targets specifically the Lys-40 on the α-tubulin, 
when the polypeptide is fully assembled in the microtubule structure (acetylation of cytosolic 
tubulin heterodimer is minimal, if not negligible) [55]. In this configuration, the Lys-40 on the α-
tubulin is exposed on the lumen of the microtubule and not on the cytosol, making this site 
completely unavailable to any cytoplasmic enzyme.  Several mechanisms have been proposed to 
explain this apparent contradiction: in one scenario, α-TAT1 would enter in the lumen of 
microtubule during the microtubule assembly, or on the opened (un-capped) luminal end in 
shrinking/kinetically stable microtubules. In this model the acetylation on the stable fraction of 
microtubules would occur because the slow enzymatic activity of the α-TAT1, which would 
happen when the region of the enzyme incorporation has already turned into a stable domain. A 
second scenario hypothesizes the presence of transient lateral opening of the microtubule  lattice 
caused either by the transient exchange of tubulin subunit with the soluble pool (so called 
“breathing model”) [56]. This transient opening would behave as hot-spot for enzyme entry in the 
luminal space of microtubules, allowing the acetylation to occur also in capped microtubules in 
which the entrance of the enzyme trough the plus-end opening would be impossible [46, 57].  
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The acetylation process on microtubules, differ from other microtubule modifications (such as ∆2 
tubulin) because the modification is reversible. Also in this case, several potential tubulin 
deacetylases enzymes can be described, but the two major are:  1) HDAC6 (histone deacetylase 6, 
a member of class II HDAC ) [58]and 2) Sirt-2 (sirtuin 2) a member of the  non-classical HDACs, 
a less effective tubulin acetylases[59]. Chemical inhibition of these enzymes by using tubacin or 
nicotinamide (respectively for HDAC-6 and Sirt2 [60, 61]) or silencing by using siRNA/ShRNA 
strategy are common tools to induce microtubule hyperacetylation [59, 60, 62-65]. 
The biological effects on acetylation is still a matter of intense debate, probably because of the 
effect of microtubule acetylation on microtubule stability has to be mediated by secondary 
effectors[66], making the correlation with any specific phenotype very challenging to interpret and 
fully understand [44]. However some in vivo studies have shown a light alteration on intracellular 
transport mediated by kinesin-1 and dynein [67, 68], in which increased microtubule acetylation 
via HDAC6 inhibition causes a slight enhancement of kinesin-1 to microtubules and a re-
distribution of kinesin cargo (such as BDNF filled vesicles). The absence of a similar effect in an 
in vitro purified preparation indicates the requirement of secondary factors to this complex 
modulation [69, 70]. 
The presence of a marginal biological effect on acetylation or any other microtubule PTMs can be 
interpreted in different ways. A simplistic interpretation would explain the lack of a strong 
phenotype after a robust alteration of one PTM as a marginally relevant biological phenomenon. 
Another interpretation considers the complexity of the biological system especially in 
overlapping/redundant mechanism such as PTMs in protein. This interpretation (proposed by 
Carsten Janke in his 2014 review [44]) states that the Tubulin code could follow a probabilistic 
signal theory, where a change of PTMs , would not result in an abrupt interruption of a biological 
process or the determination of it, but rather a bias toward of a specific phenomenon. In other 
words, a modification of a single microtubule PTM would cause the marginal modification of a 
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signal that would be in great part compensated by the expression of overlapping 
functionally/chemically similar PTMs. However the result of this perturbation would still have its 
effect:  a loss of fine tuning for a series of process which would have important biological 
consequences, but that often can be only marginally appreciated experimentally [44, 71]. This 
would make sense especially in biologically essential processes such as organelle transport and 
other microtubule related functions in which total compromise would result in an incompatibility 
with life. 
Other microtubules post-translational modifications 
Analogously to microtubule acetylation, most of the microtubule PTMs take place in tubulin 
subunits already incorporated in the polymer. A typical example is tubulin detyrosination. This 
PTM occurs preferentially on the C-tail of α-tubulin that, except for few exceptions, has a key 
tyrosine residue. This residue is selectively removed by unknown putative carboxypeptidases when 
the subunit in incorporated in microtubules [72], and is re-tyrosinated by the tubulin tyrosine ligase 
(TTL) enzyme, where the subunit is made again available in the soluble pool [44, 73, 74]. The 
result of this differential tubulin target is the creation of a dynamic domain of microtubules that is 
rich in tyrosinated tubulin, and a stable portion that is rich in detyrosinated tubulin. However the 
presence of detyrosinated tubulin in the stable domain of microtubules is also possible because the 
convergence of other factors such as the inhibitory activity on microtubule depolymerizing agents, 
such as Kinesin 13 family members (MCAK or KIF2) [75, 76].  Another important interaction 
between detyrosinated tubulin and tubulin interacting proteins is kinesin-1. In vivo and in vitro 
studies showed the preferential binding (landing rate) and increased processivity of this molecular 
motor protein along detyrosinated microtubules [70, 77-79]. The opposite modification, the re-
tyrosination, is catalyzed by a non-redundant TTL enzyme. The presence of newly assembled, 
virtually un-modified tubulin seems to be essential for different neuronal processes [44]. First 
tyrosine tubulin is the docking site recognized by a large complex of protein localizing on the plus 
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end of the microtubule tip (plus-end binding proteins). The binding of this complex on the plus tip 
is mediated by CLIP-170, which recognize tyrosine tubulin by exposing its CAP-Gly domain 
(cytoskeleton associate protein glycine rich domain) [80]. Some domains seem to be crucial for the 
recognition of the retrograde molecular motor protein complex (dynein complex) on the plus tip of 
microtubule. The docking of this complex on this location is probably mediated by p150Glued, a 
protein that forms part of the dynein complex and that bear a CAP-Gly domain similarly to 
CLIP170 [81]. Interestingly, ablation on TTL in mouse results in premature death of mouse pups 
[82]. The TTL-KO animals have several histological alterations in the developing brain [83]. The 
absence of dynamic microtubules indeed could cause an aberrant accumulation of stable 
microtubules [84], and an irreversible inhibition of numerous processes that require a great deal of 
dynamic microtubule such as neurogenic cell division, neuronal migration and axon pathfinding. 
Polyglutamylation is another major microtubule PTM occurring on assembled tubulin polymers in 
long-lived microtubules [85].  A time course of microtubule polyglutamylation in differentiating 
neurons have shown that with the approaching of neuronal differentiation the microtubule 
polyglutamylation increases [85, 86]. This PTM is catalyzed by a group of enzymes related to TTL, 
and for this reason called Tyrosine Tubulin Ligase Like proteins (TTLs) [87, 88]. In mammals nine 
different members of this subgroup of enzyme exist, and each protein perform a slightly different 
action toward this PTM based upon the preference toward the α or β subunit or the capability to 
initiate or elongate glutamate chains [89]. The depletion of any one of these enzymes results in 
mice affected by ciliopathy, indicating the essential and not redundant role that these enzymes have 
toward polyglutamylation, and the pivotal role of this PTMs in the mobile cilia functioning [90]. 
The removal of these residues is mediated by a novel subgroup of carboxipeptidases (CCP) [91]. 
So far three separate CCP deglutamylases have been identified to reverse the action of 
polyglutamylases [91]. The depletion of this enzyme, with a resultant increase of polyglutamylation 
in mice, has drastic consequence in the central nervous system of these animals. In particular 
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Purkinje cells are the cellular target particularly sensitive to hyper-glutamylation, which will 
undergo premature degeneration in this animal model [92].  Under  molecular mechanistic point of 
view, the specific role of polyglutamylation has not been extensively studied. In the past years it 
has been demonstrated that polyglutamylation could bind to microtubule lattice specific subsets of 
tubulin poly-glutamylated sensitive proteins such as spastin [93], a microtubule-severing protein 
whose function will be illustrated later in this dissertation. 
Microtubule stability in neurons 
The dynamic character of microtubules as an intrinsic property of this polymer can be easily 
reproduced in the most diverse experimental condition, sometime very far away from a biological 
environment.  Incubation of just purified free tubulin, in the right environmental conditions (370C, 
magnesium and GTP) results in the spontaneous formation of microtubules, which will sustain 
rapid cycles of assembly and disassembly, showing it to be a potentially extremely dynamic 
polymer, already in these simple conditions [7]. However the rapid bouts of microtubule assembly 
and disassembly are not uniform from the plus tip or minus tip of microtubule. The minus tip of 
microtubule has a much lower dynamicity (means going to a lower number of assembly and 
disassembly events per unit of time) compared to the plus tip more dynamic.  Having a higher 
dynamicity also means that in order to observe an event of assembly the concentration of free 
tubulin necessary to carry out this process (called critical concentration) is lower than the one 
required in regions with a lower dynamicity (such minus tip). The mechanism that governs these 
constant bouts of assembly and disassembly has been described for the first time by the Mitchison 
and Kirscher group in 1984; proposing the so call model of Dynamic Instability [94]. In this model 
the existence at every given time of each microtubule is explained as the result of a combination of 
events of disassembly alternating to events of assembly, where the latter prevails to the first. This 
mechanism is regulated by the slow GTP hydrolysis activity of β tubulin. In order for free tubulin 
to be assembled in microtubules, the β-subunit has to be in the GTP bounding state. Briefly after 
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the polymer incorporation of tubulin, the subunits start to hydrolyze GTP to GDP. For structural 
reason, in order to be stable the microtubules must contain a region composed mostly by GTP-
tubulin on the plus-end [26]. If this region is rapidly substituted by GDP-Tubulin depolymerization 
instead of assembly will occur. This process, in an in vitro situation, where microtubules are all 
equal and are not subject to special stabilizing factors, is stochastic and therefore in a population of 
microtubules at any given time, are going to a polymerization phase, meanwhile some are rapidly 
depolymerizing. 
However the high turnover that can be observed in this isolated system is far away from what 
actually happens in an intact biological scenario. In intact cells, microtubules have a very variable 
dynamic profile depending on the context and the compartment considered. In some regions, 
microtubules can have a higher turnover (frequency of polymerization and depolymerization 
events), and therefore are considered as more dynamic or called as labile, meanwhile in other 
compartments microtubules have an evident reduction of the frequency of catastrophe and rescue, 
and therefore are considerate stable. In specific regions of the cell, and at specific stages of its life 
(e.g. neuron in adult ages) a third classification appears evident: this class of microtubules can be 
considered “hyper-stable,” in virtue of their capability to stay in a polymerized state even in the 
most extreme microtubule-depolymerizing  conditions,  such as cold temperature [95]. This subset 
of microtubule differs from the labile and the stable because the absence of any dynamic behavior 
(remarkably different concept from the stable microtubule which have a lower, but still very well 
present dynamicity). In this work I will use the term as “cold stable” or non-dynamic microtubule 
to refer to this particular set of cytoskeleton elements [7].  The presence of one specific subset of 
microtubules (stable, labile, non-dynamic) does not preclude the co-existence of other subsets in 
the same cell, and actually the opposite is quite common, where the co-existence of all the three 
classes of microtubules shape the entire microtubule cytoskeleton. A classic example are 
developing neurons where microtubules in specialized regions such as the growth cone are very 
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dynamic (hence full of labile microtubule), meanwhile in the axon shaft a higher percentage of 
microtubules are stable and, although in small amount, even hyper-stable [7, 96].  A compelling 
question therefore is how microtubules can alter their dynamic profile? The answer, although to 
date not completely explained in details, relies on the combination of PTMs and binding with 
microtubule-associated proteins (MAPS) [97]. In neurons the non-dynamic/ hyper-stable fraction 
of microtubule is obtained by an unusual PTM (for microtubules) called poly-amination, where a 
great deal of positive charge is added to the polymer (mean while the majority of other PTMs are 
either neutral or negatively charged) [95, 98].   
MAPs such as MAP-6, or Tau or MAP2 are responsible for creating stable microtubules. This 
variability in the dynamic character of microtubules is vital for a proper functioning of any 
biological system, because it gives the possibility of fine tuning and local changes in the 
microtubule cytoskeleton biophysical property to make the entire cell more adapt to a specific 
environmental variation [7, 99-101]. The division of these three different microtubule behaviors is 
not just theoretical and actually come from a large series of experiments performed in the early 90s 
from Baas and Black. The labile-stable fraction was described for the first time in neurons by 
incubating neurons with a medium concentrated with nocodazole, which in time-dependent 
manner, will selectively depolymerize labile microtubule, and then much slowly and not 
completely the stable domain. The most sensitive fraction of tubulin already depolymerized after 
15 minutes of incubation had obviously a more dynamic property than the rest of microtubules, and 
for this reason is called labile. The hyper-stable/non-dynamic fraction was instead accidentally 
discovered by a cold treatment of tubulin, in which the low temperature is not capable to polymerize 
this fraction of purified microtubules [102].  
Microtubule-severing proteins 
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Within the constantly growing list of microtubule binding /regulating proteins, the microtubule- 
severing proteins is a subfamily that has particularly strong implication in neuronal morphology 
[103-105]. Microtubule severing can be defined as the enzymatic reaction that causes the 
fragmentation of a longer microtubule into a shorter piece, by the generation of an internal breaks 
[106].  This subgroup of proteins belongs to the big AAA superfamily (ATPase associated with 
diverse cellular activity), based upon the strong similarity on the catalytic site [107, 108]. So far 
eight different homologs have been identified: Spastin, Katanin, Fidgetin, VPS4, Katanin-like 1/2, 
Fidgetin like 1/2. Within these, the first three (Spastin, Katanin and Fidgetin) have been 
demonstrated to sever microtubules both in cells and in vitro. VSP4 is a paralog in mammalian, 
that does not sever microtubule but rather participates in endosomal trafficking and endoplasmic 
reticulum remodeling [106, 109].  
The effect on neuronal cytoskeleton of a microtubule-severing event can have very different 
outcomes depending on the cytoplasmic context and on the protein factors that are associated with 
those microtubule pieces. If the fragments are composed by labile microtubules, the severing will 
result inexorably in a rapid depolymerization. If the severed fragments were part of a stable 
microtubule, these can depolymerize like the labile fragments, or can act as “microtubule seeds” 
where the short fragments act as a mold and free tubulin can rapidly assemble to form a longer 
microtubule. 
The first investigations on microtubule-severing proteins were performed in C. elegans, by the 
study of Mei-1 and MEI-2 proteins, the orthologs of p60 katanin-like and its regulatory subunit 
p80-katanin in vertebrates. In C. elegans oocyte knockouts for katanin, a significant decrease of 
total microtubule mass in the meiotic spindle together with a minimal loss of soluble tubulin was 
observed [110, 111]. In these experiments, the researchers speculated that the unusual phenotype 
was the result of an insufficient severing from a putative microtubule-severing enzyme, which 
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would cause a reduction of microtubule ``seeds`` that could grow and increase the overall 
microtubule mass in the oocytes.   
The effect of microtubule severing in living cells was further elucidated by studies on katanin in a 
plant system (A. thaliana). In this system, the microtubule- severing activity was necessary to allow 
the parallel orientation of cortical microtubules for the directional deposition of cellulose fibers to 
form the vegetal cellular wall. Reduction of katanin levels in A. thaliana cells resulted in a striking 
phenotype where the deposition of these fibers was very disorganized [112]. Again, it was also 
speculated the existence of an enzyme capable to sever microtubules to allow their uniformly 
orientation in another system.  
The following studies in Drosophila larvae and cell lines definitively demonstrated the existence 
and the effect of  microtubule-severing activity of spastin at the beginning, katanin immediately 
after and finally with Fidgetin [113]. The biological actions of each of these three proteins were in 
some cases overlapped, in other divergent. For example in the Drosophila S2 cell line, Spastin and 
Fidgetin localize around the centrosome and perform severing on the minus-end and perform 
minus-end depolymerization. Conversely katanin’s enzymatic activity performs a plus-end 
depolymerization [113].   
The crystallographic structure of katanin and spastin has been already resolved [114-116]. These 
two enzymes, different from almost all the other AAA protein family members, can oligomerize to 
form very complex quaternary structures [114]. These enzymes utilize ATP to perform the 
enzymatic activity. Because of this, they can be present in two different forms: the ADP-bound 
form, which keeps the polypeptide in a monomeric form, and the ATP bound form that would cause 
its oligomerization in a hexameric form. In a highly isolated in vitro environment the 
oligomerization of spastin requires a relatively high concentration of the enzyme, probably too high 
in a physiological scenario. However, the critical concentration for spastin or katanin to oligomerize 
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can be dramatically lowered if in the reaction mix there are microtubules. The presence of tubulin 
polymers allows the enzyme to dock on the surface and induce a fast hexamerization [114, 116]. 
The enzyme hexamer shows particular structural characteristics that are very important for its 
catalytic activity: the six subunits form a central channel composed by helices with several 
positively charged amino acids, whose function is to specifically recognize the un-structured C-
terminal tail of tubulin, usually negatively charged by the presence of several glutamate residues. 
The interaction of the enzyme’s internal channel with the (negative) C-terminal tail of tubulin, 
merged with the conformational changes occurring at the enzyme hexamer after ATP hydrolysis, 
causes the continuous tuck of the tubulin subunit outside the microtubule lattice. This in turn results 
in an overall reduction of the lateral protofilament interactions, causing the formation of structural 
defects in the microtubule lattice. The following extraction of several tubulin subunits around the 
same microtubule region forms a breakage point that will resolve in a microtubule- severing event 
[106, 114].  
Despite the fact that experiments on microtubule-severing protein are still in a phase of developing, 
many exciting discoveries have been made, especially in the developing central nervous system, 
where all of the three recognized microtubule- severing proteins, katanin, spastin and fidgetin are 
expressed at the highest level (comparatively to the value in other systems) [117].  
 
Katanin 
The neuronal function of Katanin (the catalytic subunit, p60 katanin) has been demonstrated in the 
early phase of neuronal development, regulating processes such as axonal outgrowth [109, 118]. 
The depletion of katanin in developing neuron reduces the capability of a developing axon to 
properly extend, and the lack of its microtubule-severing activity around the centrosome, causing 
the accumulation of long microtubules anchored to this structure. The explanation of this complex 
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phenotype could lie on the relation between the newly formed microtubules in the centrosome and 
their capability to act as seeds in the axon to boost the local microtubule mass. In a physiological 
condition, microtubules originated de novo in the centrosome are periodically severed around the 
minus-end to be transported in the axon to increase the microtubule mass. The absence of this 
abscission from the centrosome results in a much lower number of microtubules transported in the 
axon, which in turn will negatively affect processes such axon growth that needs the continuous 
supply of microtubules to properly grow [118].  Just recently, a series of interesting work has started 
to unravel the regulation of its catalytic activity.  Katanin in neurons seems to have a higher 
preference toward acetylated microtubules [119]. Its catalytic activity is limited by the steric 
inhibition of specific MAPs which they intercalate between the severing enzyme and the 
microtubules, protecting the cytoskeleton polymer from beingsevered. The most remarkable MAP 
acting with this protective mechanism is tau, preferentially localized in the axon, where 
microtubules acetylation is particularly high [120]. 
Spastin 
Study on spastin started much earlier than the discovery of its microtubule- severing activity, since 
mutation on the SPAST gene (encoding for spastin) is the chief caus of hereditary spastic paraplegia, 
a non-progressive neurodegenerative condition causing the selective impairment of lower limb 
mobility[121].  
Pioneering studies on Drosophila unravel the molecular and cellular action of this enzyme in 
eukaryotic cells. Spastin depletion in fruit flies cause aberrant increases of synaptic  and satellite 
boutons in neuromuscular junctions in third instar larvae. In zebrafish, reduced level of spastin 
causes severe diminution of axonal outgrowth, loss of connectivity and extended neuronal 
apoptosis [122-124]. The data relative to the effect in invertebrate and in zebrafish suggest a 
possible mechanism of action of spastin mutation in HSP, where the lack of sufficient severing 
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would cause detrimental effects on axons from neurons of the corticospinal tract [125]. This 
speculation will be of interest in my second part of my research activity and extensively evaluated.  
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CHAPTER 1: VERTEBRATE FIDGETIN RESTRAINS AXONAL GROWTH BY SEVERING 
LABILE DOMAINS OF MICROTUBULES 
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Introduction 
In the axon, each microtubule consists of a stable domain from which can elongate a labile domain 
[126, 127]. The stable and labile domains are situated toward the minus and plus ends of the 
microtubule respectively, with the labile portion of the microtubule directed toward the tip of the 
axon. For axons to grow in a robust fashion, there must be an expansion of the microtubule array, 
and especially of the labile domains. Also important for axonal growth is a process whereby long 
microtubules are severed into shorter ones by proteins that tug at the microtubule lattice to induce 
breakage [114]. If the breakage occurs in the stable domain of a microtubule, the result is two new 
microtubules, both capable of growing longer. This allows for an increase in microtubule number, 
locally within the axon, for example at sites of branch formation [104, 128]. If this breakage were 
to occur in a labile domain, the expected result would be just one microtubule that is shorter than 
the original, as a microtubule with no stable domain would depolymerize completely. Traditional, 
microtubule-severing proteins like katanin and spastin, preferentially sever microtubules in the 
stable domain [129, 130]. In theory, a microtubule-severing protein that targets the labile domain 
could be important for limiting the expansion of the microtubule array of the axon to modulate its 
growth. While Drosophila fidgetin is a traditional microtubule-severing protein [113], its vertebrate 
ortholog diverges in sequence and structure [131], and yet is still able to sever microtubules [132]. 
Results of the present studies indicate that vertebrate fidgetin regulates neuronal development by 
targeting labile domains of microtubules.  
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Results 
Fidgetin depletion affects axonal development and microtubules in Drosophila. The effects of 
knocking down Drosophila fidgetin from fly neurons in the neuromuscular junction (NMJ) were 
first investigated. The Gal4/UAS system was used to express an RNAi hairpin targeting the 
Drosophila fidgetin gene (CG3326, or Fgn) under UAS control (UAS:Fgn-RNAi). Expression was 
limited to post-mitotic neurons using the Elav-gal4 driver [133-135]. The total number of synaptic 
contacts (boutons) was significantly higher in fidgetin -knockdown animals (fig 1B, 1E) compared 
to outcrossed control (Ctl) animals (fig 1A, 1E). The number of satellite boutons (which are small 
growths of presynaptic membranes that extend out from axonal terminal arbors) in fidgetin-
knockdown animals (arrows in fig 1D, 1E) was greater than Ctls (fig 1C, 1E). Increased number 
of satellite boutons has been observed in flies bearing mutations to other microtubule-severing 
proteins [122] [136]. A significant increase in the ratio of acetylated to total tubulin (measured by 
quantifying fluorescence intensity) was observed in the axonal shaft and distal synapse, compared 
to two independent control RNAi lines (Ctl1, Ctl2) (fig 1F). This was due to a significant increase 
in microtubule acetylation in these areas, as total tubulin levels remained relatively unchanged (fig 
1F). A similar result has been reported in Drosophila neurons with compromised katanin [136]. 
These results are consistent with Drosophila fidgetin behaving similarly to traditional microtubule-
severing proteins in the neurons of the fly.  
 
Fidgetin expression in developing neurons.  
Fidgetin was discovered in vertebrates as a gene spontaneously mutated in a mouse strain that 
displayed a fidgeting phenotype [131, 137]. As shown in fig 2A, vertebrate fidgetin  is larger than 
Drosophila fidgetin, with a region of over 300 amino acids toward the N-terminus that is absent 
from the fly ortholog. The Walker A motif in the AAA region is the same as in fly, but the Walker 
B has unusual amino acid substitutions. Multiple attempts at developing fidgetin antibodies in the 
past have failed for unknown reasons [131]. For this reason, a line of mice that knocks out fidgetin 
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by replacing most of the fidgetin gene for LacZ was purchased, so that fidgetin’s expression pattern 
could be observed by staining for β-galactosidase. Fidgetin expression was observed in various 
tissues, but was especially high in developing nervous tissue (fig 2B, 2b).  
Like cultures of fetal rat hippocampal neurons used in relevant previous studies [104, 120, 128, 
138], cortical neurons undergo stereotyped developmental stages in which a lamellipodium (stage 
1) becomes multiple minor processes (stage 2), one of which then becomes the axon (stage 3) after 
which the rest become dendrites (stage 4). Consistent with previous studies with mouse GFP- 
fidgetin [131], ectopically expressed rat GFP-fidgetin was found to reside in the nucleus, but is also 
cytoplasmic, distributing throughout the neuron. The morphological effects of fidgetin 
overexpression were a shorter axon and fewer immature processes (fig 2C and 2c, quantification 
fig 2E). There was no evidence of short fragmented microtubules as a result of fidgetin expression. 
For example, in fig 2D and 2d, long microtubules appear in the growth cone in GFP- fidgetin-
expressing neurons as well as Ctl GFP-expressing neurons, without any obvious short microtubule 
fragments. Per unit length of axon, there was no difference in microtubule levels in Ctl and fidgetin-
depleted axons (fig 2E). Whether the construct was GFP- fidgetin or fidgetin-GFP or whether a 
flag tag was used, no fragmentation of microtubules was observed in neurons or in rat fibroblasts 
(Sup fig 1). 
 
Effects of fidgetin depletion on cultured vertebrate neurons. siRNA was introduced just prior to 
plating. After 2 days of protein depletion, dense cultures were re-plated at a lower density to 
quantify differences in neuronal morphology when processes were permitted to grow anew. A day 
after re-plating, total number of minor processes per cell body was roughly doubled in fidgetin-
depleted neurons (fig 2G and 2g) compared to Ctl (fig 2F and 2f), and fidgetin -depleted neurons 
had significantly longer axons (see also fig 2H and 2h, which respectively show tracings of 
additional Ctl and fidgetin -depleted neurons). Differentiation was accelerated as a result of fidgetin 
depletion, with fidgetin-depleted cultures at 24 hours (hrs) having a significantly higher percentage 
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of neurons in stage 3 compared to Ctl siRNA, and a corresponding reduction in the percentage of 
neurons in stage 1. Morphological effects of fidgetin depletion were essentially the inverse of the 
effects resulting from overexpression. Data are shown in fig 2I. For confirmation of knockdown, 
GFP-fidgetin was expressed in fibroblasts or neurons together with the siRNA for 24 hrs. In 
Western blot analyses, the GFP-fidgetin band, detected with a GFP antibody, was reduced by over 
70% in the cultures transfected with fidgetin siRNA compared to those transfected with Ctl siRNA 
(fig 2J). Similar results were obtained on cultures in which each of the siRNA sequences was used 
individually (Sup fig 2). 
 
Fidgetin depletion increases labile microtubule mass in axons.   
In neurons depleted of fidgetin, there was a 53± 8.9% increase in microtubule mass relative to Ctls 
as assessed by Western blotting (fig 3C), and a 62±8.63% increase in microtubule mass per unit 
area of axon as assessed by quantitative immunofluorescence (IF) (fig 3d). Nocodazole sensitivity 
was used to discern the stable and labile fractions of the microtubule mass [126]. After 30 min of 
drug treatment, the microtubule levels were indistinguishable from the corresponding drug-treated 
Ctls, as assessed with either Western blotting or IF (fig 3C, 3c, and 3d), indicating that the 
microtubule  mass added as a result of fidgetin depletion is entirely labile.  
 
GFP-EB3 (which tracks dynamic plus ends of microtubules) was expressed at the time of re-plating 
in neurons that had been transfected 2 days earlier with either fidgetin or Ctl siRNA. No difference 
in the number of the GFP-EB3 “comets” was found between fidgetin -depleted and Ctl axons, nor 
were there any differences in the rate or duration of the comets (fig 3A). These results, in 
conjunction with the results of the nocodazole study, suggest that fidgetin depletion does not 
increase microtubule number and therefore must lengthen the labile domains of microtubules (fig 
3B). By contrast, knockdown of Drosophila fidgetin did not increase microtubule  levels, but 
resulted in a higher proportion of the microtubules being acetylated (fig 3B). 
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Fidgetin depletion decreases ratio of acetylated to total tubulin in the axon. Cultures (Ctl-siRNA or 
fidgetin -siRNA) double-labeled for IF visualization of total or acetylated tubulin in microtubules 
revealed that total microtubule levels were elevated in the fidgetin-depleted cultures but acetylated 
microtubule levels remained roughly the same as in Ctl neurons (fig 4A and 4a). This same 
reduction in the ratio of acetylated to total tubulin relative to Ctls was observed by Western blotting 
of the cultured neurons (fig 4B and 4b), and by immunohistochemistry on E18.5 brain of the 
fidgetin knockout/reporter mouse (fig 4C-F).  
 
To investigate whether fidgetin could be specifically targeting unacetylated tubulin, the same 
morphological experiments described earlier were conducted in the presence of tubacin, an 
inhibitor of HDAC6, the principal tubulin deacetylase in vertebrate cells [119]. Higher 
concentrations of tubacin can alter neuronal morphology, which is not unexpected given that the 
acetylation status of the microtubule affects how it interacts with a variety of different microtubule-
related proteins. Chosen here was a lower concentration of the drug that had no statistically 
significant effect on axon length or process number, relative to DMSO (vehicle)-treated Ctls. 
However, even at this low dosage, there was an increase in tubulin acetylation, as assessed by IF 
(ratio-imaging of acetylated to total tubulin; fig 4G and 4g) and by Western blotting (fig 4H). 
Treatment of neurons with this dose of tubacin prevented fidgetin siRNA from increasing axon 
length or minor process number relative to Ctl siRNA (fig 4I, upper graphs), and prevented 
overexpression of fidgetin from reducing axon length and process number (fig 4J).  
 
Because acetyl transferases and deacetylases do not exclusively affect tubulin and may have other 
effects on microtubules apart from their acetylation status, another approach was taken to further 
investigate. The chief tubulin acetyl transferase in vertebrate cells, namely α-TAT1 [139], was 
overexpressed. A mutant form of α-TAT1 (called α-TAT1 D157N) that cannot acetylate tubulin 
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but presumably can do anything else α-TAT1 may do was used as Ctl. Validation of the wild-type 
construct but not the mutant to increase microtubule acetylation is shown in fig 4h. These constructs 
were transfected as GFP fusions into fetal cortical neurons just prior to re-plating neurons that had 
been transfected with fidgetin siRNA 2 days prior. Two days later, the lengths of the axons and the 
number of minor processes from neurons expressing the constructs were quantified. Consistent 
with the tubacin results, both the increase in axon length and minor process number resulting from 
fidgetin depletion were preserved in the presence of α-TAT1 D157N, but were obliterated by the 
wild-type α-TAT1. Quantification of these results is shown in fig 4I (lower graphs). Together, 
these and the tubacin results indicate that morphological changes resulting from increasing or 
decreasing the levels of fidgetin depend on the presence of poorly acetylated microtubule domains.  
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Discussion 
 
The present results indicate that vertebrate fidgetin functions during development to tamp back the 
elongation of the labile domains of microtubules so that they assemble in a regulated fashion. 
Overexpression of vertebrate fidgetin does not result in obvious loss of microtubule mass from cells 
in which the labile domains are not expanding, but does suppress normal axonal elongation, a 
process that depends on the expansion of labile domains. Accordingly, depletion of vertebrate 
fidgetin results in longer labile microtubule domains and longer axons. Changes in process number 
resulting from alterations in fidgetin levels can also be explained this way. The situation is different 
in Drosophila, where the data suggest that fidgetin functions as a traditional microtubule-severing 
protein, preferentially severing stable microtubule domains. Unlike flies, which only have one 
fidgetin gene, vertebrates have two fidgetin-like genes [137], which may have allowed fidgetin itself 
to diverge. Vertebrate axons are much longer than Drosophila axons, which may be why 
vertebrates evolved machinery dissimilar from flies for regulating the growth capacity of the axon. 
 
As to mechanism, an initial idea was that vertebrate fidgetin might co-hexamerize or co-dimerize 
with spastin, and thereby act as a dominant-negative to spastin’s function. This idea came to mind 
because the phenotype of fidgetin knockdown is similar to that of spastin overexpression, especially 
with regard to higher numbers of minor processes [104]. Another idea is that the unique properties 
of vertebrate fidgetin  may result from the N-terminal domain of vertebrate fidgetin absent from 
invertebrate orthologs acting in a regulatory fashion, similar to the situation with certain kinesins, 
where an inhibitory domain can fold over to suppress the activity of the functional domain [140]. 
However, neither of these ideas easily explains how fidgetin preferentially severs labile domains 
of microtubules. To this point, perhaps the amino acid substitutions in the Walker B domain weaken 
the ATPase activity such that vertebrate fidgetin is only strong enough to break the lattice of the 
microtubule where it is weakest. This could result in a preference for the region of the microtubule 
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toward its plus end, where much of the lattice has not yet fully closed. However, this would contrast 
with in vitro data suggesting that vertebrate fidgetin has a preference for minus ends of 
microtubules [132]. The present results support another possibility, namely that vertebrate fidgetin 
targets labile domains of microtubules through a preference for unacetylated tubulin. This idea is 
appealing because it would make fidgetin the functional inverse of katanin, which targets stable 
domains through a preference for acetylated tubulin [119, 136].  
Finally, there is the potential for therapeutic application. Inhibition of fidgetin might be useful for 
treating neurodegenerative diseases as well as nerve injury, as a boost in labile microtubule  mass 
may restore lost microtubule mass and/or enable a regenerating axon to grow with more vitality 
[16]. 
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Material and Methods 
 
Fidgetin conditional knockdown flies. Transgenic fly lines UAS: CG3326-RNAi (abbreviated as 
UAS:Fgn-RNAi here) were obtained from the Vienna Drosophila Resource Center (stock #24746). 
RNAi expression was restricted to neurons by using the Elavc155-Gal4 driver. Abdominal segment 
A3 from muscle 6/7 of third instar larvae was used for NMJ analysis. Immunohistochemistry was 
performed as previously described [141]. Primary antibodies were: anti-βIII-tubulin (Biolegend) 
specific for neurons, and anti-acetylated tubulin (Sigma). Fluorescently conjugated α-HRP (1:125, 
Jackson Laboratories) was used to visualize neuronal membranes. NMJ images were obtained using 
an Olympus Fluoview 1000 laser scanning confocal microscope.  
 
Fidgetin knockout/reporter mouse. A fidgetin knockout/reporter mouse (Strain Name: B6.129-
Figntm1Frk/Frk) in which a beta-galactosidase reporter gene was inserted into the fidgetin gene, 
replacing its catalytic domain [137], was purchased from Jackson Laboratory. Heterozygotes are 
fertile, while homozygotes die prenatally. X-gal staining of homozygote fetuses was conducted at 
E12.5. Brain immunohistochemistry for βIII-tubulin and acetylated tubulin was performed on 
homozygotes fetuses at E18.5 (sagittal 20 μm sections) with the same antibodies used for the fly 
studies. Images were acquired with the confocal Leica TCS SP2 VIS/405.  
 
DNA constructs and siRNA. mEmerald-Fidgetin (termed GFP- fidgetin, as mEmerald is a modified 
GFP) and FLAG- fidgetin were generated from rat fidgetin (NM_001106484.1). Fidgetin -GFP and 
EB3-GFP were provided by W. Frankel and N. Galjart, respectively. EB3-GFP was obtained as 
described previously [128] α-TAT1 (pEF5B-FRT-GFP-α-TAT1) and α-TAT1 D157N (pEF5B-
FRT-GFP-α-TAT1 [D157N] were from Addgene. For siRNA experiments, cells were transfected 
with a pool of 4 rat fidgetin sequences (Sigma-Aldrich, accession numbers: 3086 XM_229979, 
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1273 NM_001106484, 2547NM_001106484, and 874 NM_001106484); or with a non-specific Ctl 
sequence (Ambion), using the nucleofector device from Amaxa as previously described [104]. The 
4 sequences that comprise the pool were also used individually. siRNA was used at 10 µM. DNA 
constructs were transfected by nucleofection into neurons or with Lipofectamine 2000 into 
fibroblasts. 
 
Experimental procedures on cultured neurons. For microtubule quantification studies, cultures were 
pre-extracted in a microtubule-stabilizing buffer to release free tubulin as described previously, 
except that the detergent was 0.1% TritonX100, prior to further processing for IF or Western 
blotting [126]. Analyses were performed after 0 min, 30 min or 4 hrs in 2 µg/ml nocodazole or 
DMSO control [102]. For all other IF preparation, cells were fixed in 4% PFA and then post-
extracted with 0.1% Triton. Images were acquired using identical exposure and other settings, thus 
allowing the comparisons between experimental groups. Ratio images of cultured neurons were 
obtained using the Zeiss Axiovert LSM 5 Pascal system with a HeNe laser microscope with no 
optical sectioning during imaging acquisition. Western blotting was performed by standard 
procedures, except that for the microtubule quantification experiments, the internal control was 
histone H3 level because GAPDH was lost during the pre-extraction step required to release free 
tubulin. Axon length was measured using Axiovision 4.6 software, considering as an axon any 
process longer than 50 µm. Minor processes were considered as any process longer than 6 µm but 
shorter than 50 µm. Developmental stages were defined as described in Results. For fidgetin 
depletion studies, more than 100 cells per condition per trial were analyzed. For overexpression 
studies, 30 cells per condition were analyzed in each trial. EB3 imaging was as previously described 
[128]. Three independent trials were performed for each analysis. For microtubule acetylation 
studies, tubacin was used at 2.5 µM and the α-TAT1 constructs were used as previously described 
[139]. Three independent trials were performed in each study, and an average of at least 100 
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neurons per condition per trial was taken during the quantification. For some experiments, RFL-6, 
a rat fibroblast cell line, was used in addition to the primary cortical neurons. 
 
Statistical analyses. All of the data analyses, statistical comparison and graph were obtained by 
using SPSS 20 (IBM) and Excel (Microsoft). Data represent, if not otherwise specified, mean ± 
SD. Mean difference was considered to be significant at the 0.05 level (*p≤ 0.05). Multiple group 
comparison was performed by one-way ANOVA followed by Bonferroni post hoc, and for pair 
comparison, Student's t test. 
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Fig 1: Drosophila fidgetin knockdown increases synaptic connections in vivo. A-B show confocal images 
of third instar larval NMJs, muscles 6 and 7, labeled with α-HRP (white) to detect presynaptic neuronal 
membranes. A shows a Ctl NMJ. B shows an NMJ from a fidgetin knockdown animal (Dcr2; UAS:Fgn-
RNAi; elav-Gal4). Note the significant increase in bouton number in fidgetin knockdown animals compared 
to Ctls. C shows a representative individual bouton from control animals. D shows a bouton with associated 
satellite boutons from a fidgetin knockdown animal.  
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Fig 1(continued) :Arrows show the bouton. Arrowheads show satellites. Scale bar, A and B, 10 μm. Scale 
bar, C and D, 10 μm. E shows quantification of the number of total boutons and satellite boutons in fidgetin 
knockdown animals compared to Ctls. F shows quantification of immunofluorescence intensity of acetylated 
tubulin [24], total tubulin (middle) and ratio of acetylated to total tubulin (bottom) between fidgetin 
knockdown animals (Dcr2; UAS:Fgn-RNAi; elav-Gal4) and outcrossed Ctls (Dcr2 ;; elav-Gal4 and 
UAS:Fgn-RNAi/+) at both the axonal shaft and distal synapse near the bouton. Note the significant increase 
of the ratio of acetylated tubulin to total tubulin. Error bars represent standard error. *=p<0.05, ***=p<0.001. 
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Fig 2: Studies on vertebrate fidgetin expression in rodent neurons. A amino acid alignment of fidgetin 
(in figure abbreviated as Fgn) orthologs from rat (759 aa), mouse (759 aa) and Drosophila (523 aa). The two 
vertebrate orthologs are 99% identical but notably different from Drosophila fidgetin (see Results). B shows 
X-gal staining of fidgetin knockout/reporter mouse fetus at E12.5. Fidgetin is highly expressed in central 
nervous system regions such as brain and eye (B) and spinal cord (b). C-d show microtubule immunostaining 
(anti-βIII-tubulin antibody) in cortical neurons expressing either GFP or GFP-fidgetin. Fidgetin-
overexpressing neurons have statistically shorter axons (70.04±6.95 µm) and fewer minor  
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Fig 2(continued): processes (3.33±0.163) compared to GFP-expressing Ctl neurons (axon length: 99.44±8.0 
μm; minor process number: 5.22±0.35). Quantification is shown in E. Student's t test p ≤0.05. No difference 
in growth cone morphology or relative microtubule mass was observed as a result of fidgetin overexpression 
(D, d). Similarly, there was no significant difference in microtubule mass in the axon (Student's t test ≥0.05, 
(E) third graph from left) between Ctl GFP (484±69.42 AFU) and fidgetin-expressing neurons (552±46.95). 
Scale bars: (B): 0.5 mm; (b) 2 mm; (c): 10 μm; (d): 5 μm. F-J shows the effect on cortical neurons of fidgetin 
siRNA pool. F-h show immunostains for βIII-tubulin. F and G are stage 2 neurons from Ctl and fidgetin 
siRNA groups, respectively; while f and g stage 3 neurons from the same experimental groups. Fidgetin 
depletion increases axon length (158.59± 14.90 μm (g;I) right), minor process number (10± 0.183 (G;g;I) 
left) and rate of polarization (stage 1: 30%±5.6; Stage 2: 40±3.5; Stage 3: 31±2.5 H;I) compared to Ctl siRNA 
neurons (F,f,H) (axon length: 102.77±5.95; process number 6 ±0.47; polarization stage 1: 45 ±4.4; stage 2: 
42 ±3.5; stage 3: 14±1.7) (Student's t test p ≤0.05). Quantification is shown in (I). Validation of fidgetin 
siRNA is shown in (J) where RFL-6 cells were co-transfected GFP- fidgetin and either Ctl siRNA (left) or 
fidgetin siRNA [142]. Fidgetin siRNA reduced (Student's t test ≥0.05) by more than 70% the GFP-fidgetin 
expression observed with Ctl siRNA, as evaluated by Western blotting (Fold change: Ctl siRNA: 1±0.104; 
fidgetin siRNA: 0.28±0.194, J) and immunocytochemistry (data not shown). Scale bars: (f): 20 μm; (h): 50 
μm. 
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Fig 3: Vertebrate fidgetin depletion increases labile microtubule mass in the axon but does not alter 
microtubule number. A Cortical neurons that had been treated for 48 hrs with fidgetin  or Ctl siRNA and 
then re-plated were treated with nocodazole (0.2 µg/ml) for 0 hrs, 30 min, or 4 hrs. Cultures were pre-
extracted to release of free tubulin, and then prepared for IF or Western blotting. Fidgetin -depleted cultures 
had 52.75±8.9% greater microtubule mass compared to Ctl siRNA (one-way ANOVA p≤0.05). At 30 min 
nocodazole, microtubule mass decreased to roughly half (one-way ANOVA p≤0.05) compared to the 
nocodazole-free time-point (Ctl siRNA: 45.21±1.21% decrease; fidgetin siRNA: 54.71±15.92% decrease), 
with no difference in microtubule levels between the Ctl siRNA and fidgetin siRNA groups (one-way 
ANOVA p>0.05). Fidgetin-depleted cultures and Ctl cultures also did not differ in microtubule mass (one-
way ANOVA p≥0.05) after 4 hrs in nocodazole (Ctl siRNA: 31.97±5.46%; fidgetin siRNA: 34.78±10.27%). 
Quantification of microtubule mass in the axon by IF (B) indicates that fidgetin depletion increases the overall 
microtubule mass in the axon by 62% 
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Fig 3 Continue (Ctl siRNA: 327.09±28.26; fidgetin siRNA: 530.55±34.88; one-way ANOVA test p≤0.05). 
No differences were observed (one-way ANOVA p≥0.05) between fidgetin siRNA and Ctl siRNA after 
treatment with nocodazole (0.2 µg/ml) for 30 min (Ctl siRNA: 150.34±11.84; fidgetin siRNA: 
167.36±17.66). C Neurons were transfected at day 0 with fidgetin or Ctl siRNA and re-transfected with EB3-
GFP at the time of re-plating, so that dynamic plus ends of microtubules could be visualized as fluorescent 
comets (tracked as 1 frame per sec) during bouts of microtubule assembly. The 2 experimental groups did 
not differ (Student's t test p≥0.05) in terms of comet number (Ctl siRNA: 44.70±14.43; fidgetin siRNA: 
47.40±14.39), duration (Ctl siRNA: 10.35±0.46 sec; fidgetin siRNA: 10.82±0.33 sec) or speed (Ctl siRNA: 
0.25±0.0073 µm/sec; fidgetin siRNA: 0.23 ±0.0098 µm/sec). D Schematic shows interpretation of data. 
Drosophila fidgetin behaves similarly to spastin or katanin, targeting the stable domain of axonal 
microtubules. Knockdown causes an increase in the proportion of the microtubule that is stable, without 
altering the length of the microtubule. Vertebrate fidgetin targets the labile domain of axonal microtubules, 
such that knocking down vertebrate fidgetin increases the length of the labile domain.  
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Fig 4: Fidgetin is sensitive to acetylation status of microtubules in the axon. A and a show ratio images 
of acetylated tubulin to total βIII-tubulin displayed in fire-scale pseudo-color (white being the highest 
intensity and red being the lowest). Fidgetin siRNA neurons (a) display decrease of acetylated to total tubulin 
ratio compared to Ctl siRNA. (A) same result, by Western blot analysis, with (b) quantification indicating 
that Ctl siRNA cultures have higher ratio of acetylated to total tubulin compared to fidgetin siRNA (fold 
change: Ctl siRNA: 2.1±0.29; fidgetin siRNA: 1; student t test p≤0.05). C-e Brain immunohistochemistry of 
acetylated tubulin (C and c) and total βIII-tubulin (D and d) Fig 4 (continue) : from E18.5 wild-type mouse 
and fidgetin knockout/reporter mouse respectively. Knockout brain has a decreased ratio of acetylated to total 
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tubulin as shown in figure (e) compared to wild-type (E). Quantification is shown in (F) as fold-change 
normalized to the value of fidgetin knockout ratio value as 1. Such difference was observed in all brain areas 
analyzed (the ratio value for the WT mouse are: olfactory bulb: 2.2; cortex: 2.2; septum 1.31; thalamus: 2.6; 
pretectum: 1.9). G and g show ratio images in fire-scale pseudo-color of neurons treated with 2.5 μM tubacin 
or DMSO vehicle (Ctl), and immunostained for acetylated tubulin and total tubulin. The ratio of acetylated 
to total tubulin is higher with tubacin treatment. H Western blotting of parallel cultures, also showing increase 
in acetylated tubulin. h RFL-6 fibroblasts prepared for IF visualization of acetylated tubulin after overnight 
expression of an enzymatically inactive mutant of αTAT-1 (called αTAT-1 D157N) or the wild-type αTAT-
1. Wild-type αTAT-1 shows higher staining intensity of acetylated microtubules than the mutant. Similar 
results were obtained on neurons (data not shown). I morphological quantification of experiments similar to 
those from fig 2, except that microtubule acetylation was manipulated by either tubacin treatment or αTAT-
1 overexpression. Ctl for the former and latter were DMSO vehicle and the αTAT-1 D157N, respectively. 
Neurons depleted of fidgetin treated with vehicle (DMSO) have significantly longer axons (175±11.04 μm; 
p≤0.05, one-way ANOVA), higher number of minor processes (10±0.91 p≤0.05, one-way ANOVA) 
compared to DMSO Ctl siRNA neurons (average axon length: 105±8.29 μm; process number: 5±0.49). With 
tubacin treatment, there were no morphological differences between Ctl (average axon length: 117±6.80 μm; 
process number: 4.85±0.37) and fidgetin siRNA (average axon length: 117±9.00 μm; process number: 
6.26±0.64; p>0.05 one-way ANOVA for both measurements). Neurons depleted of fidgetin expressing 
αTAT-1 D157N have longer axons (146±9.78 μm; p≤0.05, one-way ANOVA) and higher number of minor 
processes (10±0.86; p≤0.05, one-way ANOVA) compared to αTAT-1 D157N Ctl siRNA neurons (average 
axon length: 96±8.62 μm; process number: 6±0.63). With αTAT-1 expression, there were no morphological 
differences between Ctl (average axon length: 98±8.80 μm; process number: 6±0.71) and fidgetin siRNA 
(average axon length: 110±7.21 μm; process number: 7±0.79 p>0.05; one-way ANOVA for both 
measurements). J shows the effects on morphology when GFP-fidgetin overexpressing neurons when treated 
with tubacin (2.5 μM). Neurons ectopically expressing GFP- fidgetin and treated with vehicle (DMSO) show 
reduced minor process number (3.4±0.27) and axon length (81±6.04 µm) compared to neurons expressing 
GFP in presence or absence of tubacin (minor process number: 5.1± 0.38 and 4.8± 0.38 respectively; axon 
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length 111±6.32 and 115±7.64 respectively p<0.05; one-way ANOVA). Scale bar (A), (g): 10 μm.; B: 100 
µm. *indicates p value≤0.05, value expressed as average ± S.E.M. 
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Figure 5: Overexpression of fidgetin in fibroblasts does not result in the appearance of short 
microtubule fragments, regardless of tag on fidgetin construct. A rat fibroblast cell line (RFL-6) was 
transfected with plasmids coding for: (B) fidgetin -GFP (C-terminal GFP tagging); (C) GFP- fidgetin (N-
terminal GFP tagging); (D) FLAG-fidgetin (N-terminal FLAG tagging); (A) empty vector; or (E) GFP-
spastin. Cells were fixed and immunostained to reveal microtubules. As expected, overexpressed spastin 
resulted in severing of the microtubule array into short microtubule fragments. This effect was not evident in 
the case of any of the fidgetin constructs. Scale Bar, 10 µm 
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Figure 6: Individual siRNA sequences produce the same phenotype as when they are pooled. 
Morphological analyses (axon length and minor process number) were performed on primary cortical 
neurons transfected with the Ctl siRNA or the same amount of each single sequence as the total amount of 
the pool used for studies shown in the main article. The neurons transfected with Ctl siRNA have statistically 
lower numbers of minor process and shorter axons (3.79±0.195 and 109.82±4.89 respectively, p<0.05 one 
way ANOVA) compared to the neurons transfected with a single fidgetin siRNA sequence (fidgetin siRNA 
seq.1: 6.57±0.33 and 149.61±6.10 respectively; siRNA seq.2: 6.94±0.35 and 173.23±6.10 respectively; 
siRNA seq.3: 7.97±0.46 and 173.35±8.05 respectively; siRNA seq.4: 8.10±0.38 and 164.62±6.91 
respectively). The sign * indicates a statistical p value ≤ 0.05; all values are expressed as average ± S.E.M. 
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Chapter II: Spastin mutations associated with hereditary spastic paraplegia promote 
axonal transport deficits through an isoform-specific mechanism that involves aberrant 
casein kinase II activation.
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Introduction 
Hereditary spastic paraplegia (HSP) is a debilitating disease of the central nervous system (CNS) 
in which patients suffer from spasticity and gait deficiencies that are usually adult-onset.  Axons 
of the adult corticospinal tracts selectively degenerate in a dying-back manner.  Mutations in 
SPAST (previously called SPG4), the gene that encodes a protein called spastin, are the most 
common cause of HSP, accounting for more than 40% of the cases [143].  Spastin is a member of 
a family of AAA enzymes that physiologically sever microtubules [144].  This is important 
because long microtubules in the axon must be severed into shorter pieces to undergo mobile 
events such as their ongoing transport down the axon during the life of the neuron [145, 146].  At 
least one isoform of spastin, called M1, has a hydrophobic domain capable of interacting with 
membrane, thus potentially enabling spastin to participate in membrane remodeling as well as 
microtubule severing. 
 
Based on the autosomal dominant characteristics of SPAST-based HSP (termed SPG4-HSP) as 
well as the abundance of over 200 different mutations that give rise to the disease, most workers 
have favored a pathological mechanism based on haploinsufficiency [147].  In this view, there is 
insufficient spastin to carry out its normal functions. However, there are reasons to be skeptical 
that haploinsufficiency is an adequate explanation for the disease.  There are no detectable flaws 
in neuronal development associated with spastin mutations [148], despite the fact that the demands 
for microtubule severing are greater during development than in the adult [149].  In addition, 
haploinsufficiency does not satisfactorily explain why degeneration occurs almost exclusively in 
the corticospinal tracts, nor does it account for the fact that a small number of pathogenic mutations 
are not function blocking [150].   
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A gain-of-function mechanism may better explain the pathology.  In this mechanism, the mutated 
protein misfolds, and negatively impacts biochemical pathways relevant to the functioning of 
other proteins.  SPAST has two start codons, the first of which is less efficient [151].  The vast 
majority of spastin appearing throughout the body at all stages of development and in the adult is 
the shorter isoform, termed M87 in humans or M85 in rodents.  Because of its hydrophobic domain 
(not shared by M87), M1 is especially prone to misfolding.  In studies on squid axoplasm and 
cultured mammalian neurons, truncated or mutated M1 inhibited axonal transport and perturbed 
axonal outgrowth, whereas the corresponding truncated or mutated M87 did not [117, 152].  
 
There is precedent for misfolded proteins exerting their toxicity by hyper-activating kinases, and 
for molecular motor proteins being among the most responsive targets for abnormal 
phosphorylation [153-155].  Here, we sought to ascertain whether the gain-of-function toxicity of 
mutant M1 is due to such a mechanism, and if so, to identify the relevant kinase. 
  
48 
 
 
Results 
Mutated M1 spastin impairs fast axonal transport in squid axoplasm.  Ours previous work [117] 
and other independent works recently published indicates how the expression of mutated spastin 
in neurons impairs organelle transport along the axon [156, 157].  In particular, we previously 
showed that the M1 specific isoform causes the most notable effect in fast axonal transport (FAT), 
meanwhile the shorter mutated isoform has a negligible effect. In this work we wanted to 
understand whether the impairment of axonal transport previously shown is phenomenon that can 
be caused by any pathologically relevant mutation of spastin, if there is an isoform-specific 
toxicity and which is the eventual underpinning mechanism of action.  
We initiate to evaluate alteration on axonal transport by using the fast axonal transport paradigm 
in squid giant axon. We artificially translated several human M1 mutation of spastin: four 
missense mutation (M1E442Q, M1E112Q, M1L195, M1C448Y) and one truncation mutation 
(M1-STOP) and we infused nano-molar concentration of each single mutation in a separate 
axoplasm. In all the case, the infusion of mutated spastin causes drastic reduction on anterograde 
and retrograde transport in squid axoplasm in matter of minutes (M1E442Q impairment of 12% 
anterogradely and 15% retrogradely; M1-STOP impairment of 14.7% anterogradely, and 7.7% 
retrogradely; M1 C448Y impairment of 17% anterogradely and 15% retrogradely). When we 
infuse the correspondent mutation located this time in the shorter M87 isoform, no one mutation 
was capable to compromise FAT (M87E442Q impairment of 0.63 % anterogradely and 0.8-0% 
retrogradely; , M87C448Y impairment of 0.2% anterogradely, and 8% retrogradely; M87-STOP 
impairment of 1.17% anterogradely and 0% retrogradely). These data indicate that the impairment 
on FAT induced by mutated spastin is isoform specific (occur in all the M1 isoform but not in the 
M87 isoform) and independently from the mutations (all the mutation equally affect FAT).  
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The alteration on axonal transport under the mechanistic point of view could be caused by a direct 
interaction of the mutated protein to the transport machinery or by secondary mechanisms caused 
by the activation of protein effectors, such as aberrant activation of protein kinases. To understand 
which one is the prominent phenomenon we choose two different mutations M1 we inhibit Casein 
Kinase 2 (CK2) in the perfusion buffer containing the mutated M1 mutation. For this purpose we 
chose two missense mutations: M1E112Q and M1C448Y and the truncated M1-STOP mutation. 
Treatment with relatively high concentration of CK2 inhibitor peptide reinstate the FAT to control 
level independently from the mutation (M1-STOP+ inhibitor peptide impairment 0% 
anterogradely and 0.83% retrogradely). To demonstrate the specificity on FAT by CK2 activation, 
and the absence of non-specific effect caused by the peptide, similar experiments were performed 
by using this time a different strategy of inhibition (5 µM DMAT, 2 µM TBCA chemical 
inhibitors). Also in this case the chemical inhibition of CK2 result in a prevention of FAT 
impairment in presence of mutated M1 isoforms (M1E112Q + TBCA impairment of 1.9% 
anterogradely and 0.8% retrogradely; M1-STOP + TBCA impairment of 6.25% anterogradely and 
2.5% retrogradely). 
Expression of  mutated  M1 spastin increases CK2 activity.  Under our hypothesis, the presence 
of mutated M1 spastin would cause a large series of detrimental effects in neurons, one of which 
is the impairment of FAT, by over-activating endogenous CK2. To demonstrate the connection 
between these two elements we evaluate the expression level and the activity level of CK2 in cells 
stably expressing M1-STOP or M87-STOP spastin. We initially evaluate at the gene and protein 
level the expression of CK2, by using PCR and western blotting. Neuroblastoma cells expressing 
either M1-STOP or M87-STOP have equivalent level of expression of CK2 either at mRNA level 
(expression level normalized to cyclophilin:  M1-STOP = 0.95; M87-STOP= 0.8), and western 
blotting level. However, the two cells line differs considerably in terms of activity of the enzyme. 
By performing a luminescence assay coupled to the CK2 activity from M1-STOP and M87-STOP 
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cell lysate, we observed a significant increase of activity in M1-STOP expressing cells (activity 
after 32 min: 2800 AFU) compared to cells expressing M87-STOP spastin or control (activity 
value of both after 32 min: 900 AFU). The absence of differences in terms of enzymatic activity 
between the control cell and the cells expressing M87-STOP indicate that the mutated M87-STOP 
protein does not trigger any inhibitory effect on CK2 activity. We also wanted to evaluate whether 
the regimen of CK2 inhibition used in many of our experiment, was sufficient to lower the 
enzymatic activity of CK2 in cells that express M1-STOP spastin. The use of 2 µM concentration 
of inhibitor was sufficient to significantly lower the CK2 level of M1-STOP expressing cells (2800 
AFU and 300 AFU respectively). 
Mutation on M1 spastin isoform causes a selective impairment of membrane bound transport via 
a CK2 dependent mechanism.  The FAT data obtained in the squid axoplasm experiments shown 
that the expression of mutated M1 form of spastin causes an impairment of anterograde and 
retrograde transport of organelles along the squid axon. However the use of an invertebrate system 
limits our interpretation of the pathological mechanisms occurring in human pathology. For this 
reason we measure the kinetic of membrane bound organelle traffic in a eukaryotic system by 
using SH-SY5Y human neuroblastoma cell line. In particular, we measured possible alteration of 
membrane bound organelle trafficking by fluorescently labeling vesicles by the ectopic expression 
of Synaptophisin-RFP, and performing live cell imaging. We hypothesized that the stable 
expression of the M1-STOP isoform would result in a conspicuous impairment of membrane 
trafficking compared to our control cell line or cells expressing the less toxic M87 isoform. 
Coherently to our hypothesis, the expression of the M1-STOP isoform results in a diminution of 
the fraction of mobile vesicles (30 % of the total) compared to the fraction calculated in cell 
expressing M87 STOP isoform of spastin or control which mobile fraction was relatively higher 
(69.3% and 72.3% respectively). This evident M1-STOP specific impairment could be the result 
of M1isoform-specific induction of CK2 activity, as suggested by our previously described data 
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in invertebrate axoplasm. We evaluate the influence of CK2 in this process by treating the three 
different neuroblastoma cell lines with TBCA a potent CK2 inhibitor. The measurement by live 
cell imaging of membrane trafficking, indicates that the impairment of transport M1dependent can 
be prevented by reducing the CK2 activity (fraction of mobile vesicles is 60% in M1 STOP 
expressing cells treated with TBCA, and 30% in the same cells treated with DMSO vehicle). 
Interestingly the treatment of TBCA alone does not directly affect membrane trafficking since the 
CK2 inhibition does not causes significant changes in M87 STOP expressing cells or control cell 
line (number of mobile vesicles in M87 + TBCA cell line 76%  ; M87 + DMSO : 69.3%; Control 
+ TBCA : 72%; Control + DMSO 72.3%). 
Mutation of spastin causes mitochondria re-distribution in RFL-6 cells and primary cortical 
neurons.  The data on vesicle trafficking observed in stably transfected neuroblastoma indicate 
that mutated M1 could impair membrane bound organelle transport via CK2 over-activation. A 
consequence of this impairment, is the altered distribution of several different organelles such as 
mitochondria, which itself could have important pathological implication. To investigate this 
particular aspect, we analyze the mitochondria distribution in RFL-6 cells transiently expressing 
one of the two separate isoforms of mutated spastin M1C448Y or M87C448Y. Mitochondria are 
organelles which distribution in the cells is heavily dependent on transport mechanism occurring 
along the microtubule array. In a physiological context, a typical fibroblast has great part of its 
mitochondria asymmetrically clustered in one pole of the cells and a smaller fraction widely 
dispersed in the remaining regions. By labeling the mitochondria with a fluorescent probe (orange 
Mitotraker ®) we observed that high percentage of cells have mitochondria that follow this 
distribution pattern (control, non-transfected cells 85% not dispersed). Transient expression of 
RFP or mutated M87 causes a slight diminution of this percentage (65% and 59% respectively), 
with no statistical difference between these groups, indicating that the general expression of an 
ectopic protein causes a slight impairment of membrane transport, independently from the kind of 
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protein expressed. However, the temporarily expression of the mutated M1 isoform causes a 
drastic alteration of mitochondria dispersion, reducing the number of cells that have a control-like 
mitochondria distribution to a much lower level (40% of the total). These data indicate that the 
expression of the mutated M1 isoform influence the transport of mitochondria with a specific 
mechanism, not shared by the M87 counterpart. After we tested the possible involvement of CK2 
over-activation also in this phenomenon, by treating the transiently transfected cells with vehicle 
or TBCA. Treatment of TBCA does not influence mitochondria distribution in our RFP transfected 
or non-transfected control cells (75% and 14 % cells with dispersed mitochondria respectively). 
Analogously CK2 inhibition did not affect the mitochondria distribution in cell expressing the 
mutated M87 spastin isoform (60% dispersed cells in M87 C448YTBCA treated cells compared 
to 59% in M87 vehicle treated). The action of CK2 on mitochondria distribution was instead 
evident in M1C448Y, in which CK2 inhibition causes a significant reversion of the mitochondria 
distribution phenotype, having a higher number of cells with a non-dispersed mitochondria (60%), 
similar to the M87C448Y or RFP expressing cells. 
A similar experimental paradigm was also used in primary cortical neurons, a better cellular model 
to study HSP. As observed in rat fibroblast the transient expression of the M1 C448Y mutated 
isoform of spastin causes mitochondria re-distribution in primary cortical neurons (35 % cells with 
clustered mitochondria), compared to RFP transfected cells or M87C448Y transfected cells (36% 
and 34% of the total). Again, treatment with TBCA reduces the number of cells with dispersed 
mitochondria in M1C448Y over-expressing cells (35%) and does not have significant effect in 
other over-expressing cells (M87C448Y + TBCA: 33%; RFP + TBCA: 32%). A general decrease 
of number of dispersed mitochondria was also observed in non-transfected neurons (non-
transfected DMSO: 13%, non-transfected +TBCA: 18%). 
Expression of Mutated M1 spastin causes Golgi dispersion as a sign of dynein inhibition.  As in 
many other cell systems the organelle distribution and sorting depend upon the fine equilibrium 
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of their anterograde and retrograde transport, which is mainly orchestrated by conventional kinesin 
and dynein. As corollary, an imbalance of these transport mechanisms would result in altered 
distribution of organelles. One of the best-characterized examples of this re-distribution is the 
Golgi apparatus that appear disperse in correspondence of dynein inhibition [158, 159].  By using 
immunocytochemistry technique we investigated the possible alteration of dynein activity by 
performing a morphological analysis of Golgi distribution in stably transfected M1-STOP, M87-
STOP and control SHS5Y cells. The cells expressing the M1-STOP isoform of spastin have a 
significant dispersion of Golgi apparatus (5.6% of total cellular area) compared to M87-STOP and 
GFP control (3.8% and 3.9 % of total cellular area). To evaluate the dependence of this phenomena 
with an increase of CK2 activity we treated for 24 hrs the cells with TBCA. The inhibition of CK2 
is capable to re-induce the physiological clustering of Golgi apparatus in M1-STOP cells (M1-
STOP +TBCA: 3.8% total area), but does not have a significant effect in cells expressing M87-
STOP spastin or GFP (3.8% total area, 3.8% total area respectively). 
  
54 
 
 
Discussion 
 
Haploinsufficiency remains the most popular explanation for SPG4-HSP, and not without good 
reason.   Over 200 different SPAST mutations that include missense, nonsense and single amino 
acid substitutions, all give rise to the same constellation of symptoms.   Abundant evidence 
suggests that the functions of spastin are regulated by the amount of spastin expression, which is 
consistent with reductions in functional spastin levels being detrimental to neurons [157, 160].  
Certain mutations would be expected to cause unstable mRNA and hence result in little or no 
mutant spastin protein, and in some patients the entire SPAST gene is deleted [161, 162].  Despite 
all of this, there are persistent reasons to question that haploinsufficiency is a sufficient explanation 
for the disease.  For example, there is no correlation between the degree to which a mutation 
disables spastin function and the severity of the disease [163].  As for the predicted near absence 
of the protein with mutations expected to produce unstable mRNA, there is precedent for very low 
levels of mutant proteins, too low to be detected by conventional techniques, still being sufficient 
to cause neurodegeneration  [164, 165].  Moreover, the only evidence on the lack of detectable 
mutant spastin in patients comes from cells that are not corticospinal neurons [129].  In fact, the 
one SPG4-HSP patient whose post-mortem spinal cord tissue has been investigated showed a 
major band on Western blots corresponding to mutant M1 [166].  As for patients with SPAST 
deletions, such deletions can also result in deletions of neighboring genes [167], and hence the 
situation in these patients is not straightforward to interpret.  
Despite the controversy, most model systems in the HSP community have been SPAST knockouts 
or knockdowns, and hence when using these models, the logic becomes circular as to whether 
haploinsufficiency is the mechanism of the disease.  For example, two different SPAST knockout 
mouse models have been generated [168, 169], as well as knockout or knockdown flies [122, 124, 
170].  In a recent paper aimed at pharmacological rescue of HSP phenotypes, various different 
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models were used including C. elegans, Drosophila and zebrafish, and in all cases, the animals 
were SPAST knockouts (Julien 2016).  The question becomes whether these lines of research are 
really modeling the disease or whether they are only modeling the phenotype of spastin knockout.  
In our own studies on Drosophila, expression of human mutant spastin caused a stronger HSP-
like phenotype than knocking out endogenous spastin [152].  The same is true in cultured 
mammalian neurons, comparing spastin knockdown with expression of the pathogenic mutant 
spastin [117, 128, 150, 152].  The two different SPAST knockout mouse models mentioned above 
show almost no phenotype [168, 169], whereas a mild HSP-like phenotype has recently been 
shown in homozygotes of a new mutant mouse into which an HSP-like mutation was introduced 
into an endogenous mouse SPAST gene [171].  If haploinsufficiency were the more logical 
conclusion on the basis of the mouse models, the knockout mouse should display a stronger 
phenotype than the animal with half-normal and half-mutant spastin, and yet the opposite is true.  
To date, mechanism-based therapeutic ideas for treatment of SPG4-HSP have centered on the use 
of microtubule-active drugs such as vinblastine, used at very low concentrations [170, 172, 173].   
The premise has been that neurons with too little spastin suffer from hyper-stabilized microtubule 
arrays, because spastin normally pairs back the stable domains of axonal microtubules.  Indeed, 
experimental knockdown of spastin in animal and cell culture models results in higher levels of 
stable microtubules [129].  Vinblastine used at nanomolar concentrations is a “kinetic stabilizer” 
of microtubules, meaning that it permits slower than normal subunit exchange of the microtubule 
with the free tubulin pool, but does not permit net elongation of the microtubule [16].  Thus the 
reported therapeutic benefit of vinblastine on spastin haploinsufficient cells is confusing, as the 
drug would not be expected to destabilize the microtubules as other workers have suggested, but 
rather to kinetically stabilize them.  In our recent study, mutant spastin that contain the 
microtubule-binding domain were shown to bind to microtubules, especially in the perikaryal 
region of cells, and stabilize the microtubules [152].  However, the unbound mutant spastin (both 
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M1 and M87) had the inverse effect, namely to destabilize microtubules.  Our present studies on 
our new neuroblastoma cell lines provide a hint of microtubule destabilization as a result of mutant 
spastin expression, as there is a minor elevation in the proportion of tubulin that is tyrosinated.  
Given that the microtubule destabilization effects documented here and in our previous study are 
not M1-specific, there is reason to doubt that microtubule destabilization is the primary gain-of-
function effect of mutant spastin, assuming that it is mutant M1 that accumulates and not mutant 
M87.   
Deficits in axonal transport are associated with various neurodegenerative diseases [174-176].  A 
deficit in axonal transport may be especially problematic for the corticospinal tract because their 
axons are among the longest in the body [177] .  Impairment of axonal transport has been 
documented not only in HSP associated with SPAST mutations [157, 172], but also in HSP 
associated with mutations of other genes [178-180].  Our previous work infusing squid axoplasm 
with truncated mouse spastin demonstrated that axonal transport is impaired by truncated M1 but 
not by comparable levels of truncated mouse M85[117]. Here, instead of using mouse spastin and 
instead of using a truncation to approximate pathogenic mutation, we used human spastin with 
actual mutations (such as E442Q, E112Q, L195I and C448Y) that occur in HSP patients.  In all 
such mutations tested, infusion of mutant M1 impaired axonal transport in squid axoplasm, while 
the corresponding mutant M87 did not.  Consistent with these data, alterations in vesicle transport 
were observed in neuroblastoma cells expressing truncated M1 but not truncated M87, and the 
same was true of organelle mis-localizations in fibroblasts expressing mutant M1 but not mutant 
M87. 
How might mutant M1 inhibit axonal transport and cause organelle mis-localization?   It was 
previously speculated that mutant spastin bind along microtubules and prevent them from 
interacting with molecular motor proteins [181].   We think this is an unlikely explanation because 
some mutant spastin do not have a microtubule-binding domain, and the squid work demonstrates 
57 
 
 
that mutant M1 is toxic to axonal transport at levels too low to do so simply by coating the surface 
of microtubules.  The stoichiometry is also problematic for mutant spastin molecules to directly 
interact with and thereby inactivate molecular motor proteins.  It is more feasible that an 
amplification process would be involved to magnify the biological action of mutated spastin on 
molecular motor proteins.  There is precedent for aberrant activation of protein kinases by disease-
related misfolded proteins such as Huntingtin [155], Presenilin [182] and fibrillar Tau [183] . 
While the theme is the same, the particular kinase varies, depending on the disease. Our present 
studies demonstrate the reversal of the mutant M1-specific transport deficits and organelle mis-
localizations by inhibitors of CK2 but no other kinase tested, and this was true for a range of 
different SPAST mutations. CK2 is known to phosphorylate both cytoplasmic dynein [184] and 
kinesin-1 [185], and at least in the case of the latter, in a manner that mediates its release from 
vesicles.   These results are consistent with a scenario whereby mutant M1 elicits its effects on 
axonal transport and organelle distribution by aberrant phosphorylation of molecular motor 
proteins resulting from hyperactivation of CK2.  On this basis, we propose that CK2 inhibitors 
may offer a novel strategy for alleviating symptoms of SPG4-HSP, although we acknowledge that 
the inhibitors would have to be delivered in moderation and targeted to the particular neurons that 
suffer most, given that CK2 is important for many different signaling events.   
In the case of tau fibrils, it has been suggested that the relevant domain of tau that causes kinase 
hyperactivation normally influences motor protein phosphorylation in a regulated fashion [183].  
The same general principle may apply in the case of M1 and CK2, with M1 normally influencing 
the phosphorylation of CK2 targets.  M1 is believed to insert into membranes such as endoplasmic 
reticulum and endosomes, and contribute to their shape [142, 186, 187].  Perhaps M1 does so in 
part by influencing the phosphorylation of CK2 targets relevant to membrane modeling.  Of 
course, M1 can also join with M87 to form the hexamers that sever microtubules, and CK2 targets 
might also be relevant to that process.  Reid’s laboratory has posited that spastin might functionally 
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link microtubule severing to membrane modeling during axonal branch formation and cytokinesis 
[188], and it is not unreasonable to surmise that such a linkage may involve CK2 targets such as 
molecular motor proteins. 
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Material and Methods 
In vitro translation. For studies on vesicle motility in squid axoplasm, spastin polypeptides were 
produced by in vitro transcription/translation (Promega; TnT T7 coupled Reticulocyte Lysate 
system), as previously described [189, 190].  Typically, 1-2 µg of plasmids were transcribed in a 
50 µl reaction mix, following the manufacturer’s procedures.  In vitro translation products were 
briefly centrifuged to eliminate translation machinery, and supernatants were frozen in liquid N2 
until use.  Spastin polypeptides were typically perfused at 1-10 nM levels.  To ensure that the same 
levels of spastin peptides were perfused for each experimental condition, parallel reactions were 
performed using 35S-labeled methionine (Amersham), and relative levels were quantified using 
phospho-imaging scanning methods [190].   
 
Vesicle motility assays in isolated squid axoplasm.  Axoplasm was extruded from giant axons of 
the squid Loligo pealeii (Marine Biological Laboratory) as described previously [191-193].  Axons 
were 400-600 µm in diameter and provided ≈5 µl of axoplasm.  Recombinant in vitro translated 
spastin peptides were diluted into X/2 buffer (175 mM potassium aspartate, 65 mM taurine, 35 mM 
betaine, 25 mM glycine, 10 mM HEPES, 6.5 mM MgCl2, 5 mM EGTA, 1.5 mM CaCl2, 0.5 mM 
glucose, pH 7.2) supplemented with 2-5 mM ATP.  20 µl of this mixture was added to perfusion 
chambers [194].  Preparations were analyzed on a Zeiss Axiomat with a 100X, 1.3 n.a. objective, 
and DIC optics.  Hamamatsu Argus 20 and Model 2400 CCDs were used for image processing and 
analysis.  Organelle velocities were measured with a Photonics Microscopy C2117 video 
manipulator (Hamamatsu).  All experiments were repeated at least 3 times.  Unless otherwise 
stated, the data were analyzed by ANOVA followed by post-hoc Student-Newman-Keul’s test in 
order to make all possible comparisons.    
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Cell culture.  Primary embryonic rat cortical cultures were obtained from rat embryo at age E18-
E20 following the same culture procedure described in our previous work [103].  Briefly, rat 
cortices were separated from the dissected brain, and neurons were dissociated in a single 
suspension prior to be plated in a 35 mm glass bottomed dish (14 mm diameter In Vitro 
Scientific™) at a density of 25-35.000 per dish.  The glass bottoms of the dishes had been coated 
with poly-L-lysine (P2636, Sigma) prior to adding the cells. Neurons were kept in DMEM-
astroglia conditioned media and transfected at 48 DIV, and morphological analysis was performed 
24 h post-transfection.  RFL-6 rat fibroblasts were cultured in F12K/FBs 10% media as previously 
described [152].  Two novel stably transfected cell lines based on mouse neuroblastomas (N2A) 
cells were generated, one which expresses human truncated M1 and the other which expresses the 
corresponding human truncated M87.  
 
Transient transfection of cultured cells.  Adherent primary cortical cells were transfected by using 
Cellaxess CX1 device (Cellectricon) allowing the analysis of neuronal structures such as axons, 
neuritic processes and neuronal contacts, formed before the ectopic expression of the interest 
protein. We follow the transfection protocol previously described from our lab [195] with some 
minor modifications on culture condition and total amount of DNA used. In particular, 18 µg of 
DNA was used per electroporation, and 3 individual electroporation per dishes was used to allow 
the efficient transfection of an average 5-10 neurons per dish. The transfection methods, created 
areas of distressed cells that were carefully avoided in our analysis.  Neurons were transiently 
transfected with plasmid encoding with mutated M1C448Y or M87C448Y human spastin or 
control RFP. In this experimental regimen 30 cells per condition in each experiment was used. 
Adherent RFL-6 cells were transfected by using Lipofectamine 2000 (Invitrogen), using a 
procedure previously described from our lab [138].  Cells were plated 48 hrs prior transfection at 
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density of 10.000 cells per dish, 1 µg of DNA /2.5 µl of Lipofectamine® was used per dish. This 
method allows an efficient transfection of 10-15% of the overall cell population in each dish. For 
analysis of ectopic expression of mutated spastin (M1C448Y; M87C448Y; or control RFP) an 
average of 100 cells per condition per experiment was used. 
Kinase inhibition.   As for the cultured cells, they were treated with vehicle (2 µl of DMSO) or 
TBCA (Calbiochem®,  218710), a cell permeable competitive inhibitor of Casein Kinase 2 for 24 
hrs. 
Western blotting and immunocytochemistry. For immunocytochemistry, cells were fixed with a 
microtubule stabilizing buffer (PHEM) Formaldehyde 4%, and glutaraldehyde and extracted post-
fixation with 0.1% Triton. All the quantitative immunofluorescence data were obtained by using 
identical exposure setting allowing comparison across groups. For western blotting was performed 
by using standard protocol using as GAPDH to balance loading.  For immunocytochemistry and 
western blot we use the following antibodies: Anti-Acetylated tubulin (Sigma T-6793); Anti-
Tyrosinated Tubulin (Millipore, Mab1864); Anti-βtubulin (Abcam, Ab6046) Anti-GM130 
(Abcam ab52649). 
Mitochondria distribution analysis. Mitochondria visualization was performed by incubating 
neurons or fibroblast with a working solution of Green Mitotracker® at the final concentration of 
20 nM for 20 minutes in 37C. In this analysis we considered clustered a mitochondria distribution 
in which great part of the organelle localize asymmetrically in one pole of the nucleus. We 
consider instead a mitochondria distribution as “dispersed” a spatial organization of these 
organelles in a disseminate pattern, losing the characteristic asymmetrical, perinuclear clustering. 
To perform vesicle trafficking analysis in human neuroblastoma cell line, cell were transfected by 
using a nucleofector device in a cell suspension system as already described previously [103]. 
After transfection cells were plated at density of 15.000 cells per dish and analysis of RFP 
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fluorescently labeled vesicles were obtained 48 hrs post-transfection. For the analysis of vesicle 
trafficking an average of 30 cells per condition per experiment was used. 
Live cell imaging.  Vesicle transport assay experiment was performed by using live cell imaging 
techniques.  To visualize movement of membrane bound elements, neuroblastoma cells were 
transfected with RFP-Synaptophysin.  Movies of mobile vesicles were obtained by using the 
following parameters modified by another laboratory [196]: 5 frame per second for a total length 
of 20 seconds.  We consider transport events occurring in neuritic processes which have a 
minimum length of 30 mm.  We exclude the first 5 mm of neurite most proximal to the cell body.  
Any traceable vesicle that moves for more than 3 mm during the overall length of the movie was 
considered as mobile. Conversely any vesicle moving for less than 3 mm during the entire analysis 
was considering as stationary. 
Statistical Analyses.  All of the data analyses, statistical comparisons, and graphs were obtained 
by using SPSS 20 (IBM) and Excel (Microsoft). Data represent, if not otherwise specified, mean 
± SD.  Mean difference was considered to be significant at the 0.05 level (∗p ≤ 0.05).  Multiple 
group comparison was performed by one-way ANOVA followed by Bonferroni post hoc, and for 
pair comparison, Student’s t test. 
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Figure 7: Effects of M1 and M87 mutant spastin on axonal transport.  (A) Schematic representation of 
mutant spastin proteins used in this study. Specific domains are indicated in the top graph.  The ATPase 
associated with various cellular activities (AAA, in red), microtubule-binding (MTB, in yellow), and 
microtubule-interacting and trafficking (MIT, in X) domains are shown, as well as the nuclear localization 
[125] and export (NLS) signals are indicated. M1 spastin mutant proteins were generated by mutating M87 
to  in plasmid cDNA templates (red asterisk)*, whereas M87 spastin proteins were generated by mutating 
the M1 residue (red asterisk)*.  The locations of non-sense and missense mutant residues are indicated by a 
red asterisk.  Note that truncated M1-STOP and M87-STOP lack the MTBD. (B) In vitro translation of 
cDNA constructs in A was performed in the presence of 35S-methionine. Autoradiogram analysis of 
reactions after SDS-PAGE confirms expression of M1 and M87 mutant spastin proteins. Control reactions 
(no cDNA) did not result in detectable protein synthesis. (C-H). Plots depicting results from vesicle motility 
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assays in isolated squid axoplasm. In vitro translated reactions as in B were perfused and fast axonal 
transport (FAT) rates monitored by video microscopy*. Individual velocity measurements (arrowheads) are 
plotted in function of time. Anterograde (blue arrows and line) and retrograde (reverse green arrows and 
line) FAT rates are shown. Perfusion of spastin mutants M1-C448Y (C) , M1-E442Q (D), inhibited both 
anterograde (kinesin-1-dependent*) and retrograde (cytoplasmic dynein-dependent) FAT rates. In contrast, 
their corresponding mutant M87 isoform counterparts showed no effect on FAT (E and F). Similar results 
were observed using M1 and M87 versions of HSP-related E112K and L195V mutants (see Suppl. Fig. 1). 
Inhibition of FAT by M1-STOP (G), but not M87-STOP (H) truncated spastin further suggested a toxic 
mechanism independent of spastin binding to microtubules. Quantitation of data in (I) indicates that the 
inhibitory effect of mutant spastin on FAT is M1 isoform-specific. n: number of independent experiments. 
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Figure 8: Cytotoxic effect of mutated M1 spastin in vertebrate cells.  Ectopic expression of truncated 
form of spastin (M1/M87 STOP) or missense mutation (M1C448Y) causes a series of detrimental effect in 
different cellular compartments. A Human neuroblastoma cell line (SHS5Y), stably transfected for truncated 
M1 isoform 
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Figure 6 (continue): isoform of spastin (M1-STOP) or M87 (M87-STOP), were transiently transfected with 
a RFP-Synaptophysin plasmid to measure vesicles trafficking along processes. Ectopic expression of M87 
isoform of spastin does not significantly change the vesicles trafficking compared to our control cell line 
ectopically expressing GFP (fraction of mobile vesicles in M87-STOP: 78.5 ± 4.1%, GFP control: 69.5 
±5.5%). Conversely the expression of M1-STOP mutation decreases the vesicles trafficking reducing the 
number of moving vesicles of about the half of the value of GFP control (42.5 ±5.9%). The impairment of 
vesicles transport is evident by comparing two representative kymograph of vesicles transport from a cell 
expressing M1-STOP  (top left panel) and M87-STOP (lower panel). B Effect on Golgi distribution on the 
same cell line described in A. The expression of mutated M1 causes an expansion of its surface (M1 STOP:  
5.6 ± 0.47 % Golgi surface over the total cell area area) compared to control and cell expressing the less 
toxic M87-STOP isoform (3.8 ± 0.15 % and 3.9 ± 0.11 % respectively), suggesting a possible dynein 
inhibition mechanism of action. C Stably-transfected SH-SY5Y cells expressing M1-STOP and M87 STOP 
were metabolically labeled using radiolabeled P 32, and lysates derived from these cells processed for 
immunoprecipitation using antibodies that selectively immuno-precipitate conventional kinesin (kinesin-1) 
and cytoplasmic dynein (CDyn). Autoradiogram analysis of whole cell lysates confirmed similar levels of 
P32 incorporation for M87- STOP and M1-STOP- expressing cells. However, autoradiogram analysis of 
immune-precipitates revealed increased phosphorylation of kinesin heavy [197] and light chain (KLCs) 
subunits, as well as dynein intermediate chain (DIC) subunits in cells expressing M1-STOP, compared to 
M87-STOP cells. (B) Quantitation of data in A indicates a 43%, 27% and 40% increase in net 
phosphorylation of KHC, KLC, and DIC, respectively. (C) Western blot analysis confirmed similar levels 
of KHC and DIC expression for M87-STOP and M1-STOP- expressing cells. 
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Figure 9: Inhibition of axonal transport by M1 spastin mutants is mediated by CK2. Results from 
vesicle motility assays in co-perfusion experiments. When co-perfused with M1-STOP, the pharmacological 
CK2 inhibitor TBCA (200 nM) completely prevented the effects of M1-STOP (A) on FAT (compare to Fig. 
5C). Extending these findings, the inhibitory effect of M1-STOP on FAT was also prevented by the 
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unrelated CK2-specific peptide substrate (CK2pept, 500µM) that acts as a competitive inhibitor (B). Further, 
TBCA also prevented the inhibitory effect of M1-C448Y (C) and M1-E442Q (D) on FAT. Together, these 
results indicate that CK2 mediates the toxic effect of mutant M1 spastin on FAT. n: number of independent 
experiments. 
69 
 
 
 
Figure 10: Constitutive expression of truncated M1 human spastin causes organelle distribution and 
transport alteration through a CK2-dependent mechanism.  Human neuroblastoma cell line SHS5Y 
constitutively expressing truncated M1 spastin (M1 STOP) and treated with vehicle DMSO (C), (H) have a 
significant increase of Golgi dispersion compared to cells expressing shorter truncated isoform M87 STOP 
(A), (H) or GFP treated with DMSO (M1 STOP+ DMSO:  5.6 ± 0.47 %; control GFP+DMSO : 3.8 ± 0.15 
% and  M87 STOP +DMSO3.9 ± 0.11 % Golgi surface over the total cell area area). Selective blocking of 
CK2 activity via chemical inhibition by TBCA revert the dispersion phenotype bringing the Golgi Figure 
8 (continue): surface level similar to control condition (M1-STOP +TBCA: 3.8±0.26 ; GFP +DMSO: 
3.9±0.38). Neither TBCA nor M87 expression seems to affect significatively the Golgi morphology in this 
cell line (GFP +TBCA: 3.6± 0.329; M87 STOP + DMSO 3.8±0.49 ; M87 STOP +TBCA: 3.8±0.268, (H)).   
(E-G, I) Expression of the M1-STOP causes also a vesicle transport impairment in the same cell line, here 
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measured as percentage of vesicles moving along processes (M1-STOP +DMSO (F): 42.53 ± 5.56; (E)M87 
STOP +DMSO : 69.49 ± 5.7; GFP +DMSO : 78.25 ± 4.1). This effect is also reverted by TBCA, which 
increase the number of moving vesicles in M1-STOP expressing cells ((G) 59.68 ± 10.71). Treatment with 
TBCA has negligible effect on the other experimental groups ((I) M87 STOP +TBCA: 51.91 ± 5.5; GFP 
+DMSO: 65 ± 5.5).  
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Figure 11: Mutated M1 spastin alters mitochondria distribution in neuronal and non-neuronal cells.  
Analysis of mitochondria distribution in Rat fibroblast transiently over-expressing M1 C448Y (Ac), M87 
C448Y (Aa) or RFP.  Expression of M1C448Y with DMSO vehicle (Ac), results in a an increase of 
mitochondria dispersion (number of cell with dispersed mitochondria: (62% ±3.61), meanwhile expression 
of the shorter mutated isoform M87C448Y treated with DMSO (Aa) causes minimal mitochondria re-
distribution (41±4.16%)  comparable to the effect obtainable by expressing RFP (and 31.6 ± 2.08  %, (C)). 
Treatment with specific CK2 inhibitor (TBCA) reverses the redistribution effect observed in M1C448Y 
(Ad) over-expressing cells lowering the number of cells with dispersed mitochondria to level similar to GFP 
untreated cells (38.6 ±6.65 (C)). Casein kinase inhibition has a negligible effect on distribution pattern 
((C)RFP+TBCA: 30.6 ± 11.62; (Ab) M87C448Y +TBCA: 40.56 ± 10.6) . (Ba-Bd)The reversion of the 
mitochondria distribution phenotype induced by M1C448Y via a CK2 mechanism has been observed also 
in primary cortical neurons ((Bc) M1C448Y + DMSO: 63.3 ± 3.21; (Ba)M87C448Y + DMSO: 37.0 ± 4.0; 
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RFP + DMSO: 12.28; (Bd) M1C448Y + TBCA: 38 ± 2.64; (Bb) M87C448Y + TBCA: 32.67 ± 3.52; RFP 
+ TBCA: 14.03± 11.27 (D)). 
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Figure 12: Mutated spastin has a minor or negligible effect on microtubule  PTMs:  A-D A minor 
increase (roughly 30%) of tubulin tyrosination has been observed by immunocytochemistry in cells 
expressing M1-STOP isoform of spastin  (2.6 ± 0.11 tyrosine-tubulin /total tubulin ratio) compared to 
control cell line and cell expressing the shorted M87 isoform (1.94 ± 0.11  and 1.92 ±0.15 ratio value 
respectively). Treatment with TBCA does not alter significantly acetylated tubulin ratio in any groups (M1-
STOP + TBCA: 2.1 ± 0.10; M87-STOP + TBCA: 2.0 ± 0.10; CTRL GFP + DMSO: 1.95 ±0.08). (E-F) 
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Quantitative Western blot (top right panel) shown no significant changes on tubulin acetylation. The basal 
level of tubulin acetylation, here expressed as ratio for total tubulin, does not significantly change between 
control cell line and M87 STOP + DMSO (1.18 ± 0.47) and M1-STOP +DMSO (0.9 ± 0.31). No significant 
changes were also observed after treatment with TBCA (Control + TBCA: 0.9 ± 0.25; M1-STOP + TBCA: 
1.0±0.35; M87-STOP+TBCA: 1.2±0.29). 
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Recommendation and final remarks 
Microtubule organization and regulation play a pivotal role in the physiology of neuronal 
development in the adult and developing nervous system. Morphology, appropriate connectivity, 
intracellular and cellular movements are all essential phenomena for the normal neuronal 
functionality which function would be just not possible without the presence and re-arrangement 
of microtubules [6]. 
During the life of any organism, neurodevelopment is the time where incredible complex 
morphological and physiological changes occur in a very short time frame. However the 
importance of the cytoskeleton, particularly microtubule cytoskeleton, is not limited to the 
developmental phase of nervous system, but it is absolutely necessary during the entire life of the 
organism. In this case the morphological changes and related physiological alterations are still 
intensively occurring, but on the light of fine scale tuning, where subtle changes are capable to 
induce great alteration on neuronal functionality  [198-200]. 
As already mentioned, microtubules, thanks to their plastic configuration, are key elements for 
directing a large series of processes in the nervous system [6]. This conditional plasticity, is the 
result of a balanced interaction between several regulatory proteins which will shift the microtubule 
organization toward a more dynamic polymer or more stable structure during a particular spatial-
temporal window [7].  
Microtubule-severing proteins are key regulators of microtubule cytoskeleton, and by reflection, of 
numerousness neuronal functions [106, 109]. In this dissertation we have focused on two members 
of this family in two different scenarios: the role of fidgetin in developing of the CNS and the role 
of spastin in neurodegeneration.  
In neurodevelopment our present study indicates that fidgetin depletion from vertebrate neurons is 
accompanied by an increase in the axon  dynamic of microtubule mass. We pose that fidgetin is 
present in the axon of vertebrate neurons to manage the length of the labile domains of the 
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microtubules, and thereby also control the relative proportions of labile and stable microtubule 
mass.  In this fashion, we speculated that fidgetin contributes to regulating axon growth in the fetus, 
as well as the cessation of growth when an axon has reached its target or the  pruning back of 
supernumerary axons or axonal branches that occur during development.   The way by which this 
occurs is potentially complex, because the labile domains of microtubules are not only more 
dynamic, but are also very different compositionally than the stable domains.  Stable domains are 
rich in post-translationally modified tubulin subunits [44] that establish the affinity of the 
microtubule for various molecular motors as well as other proteins that influence the various duties 
and properties of the microtubule array [201].  Thus changes in the levels or activity of fidgetin in 
the axon can have a profound impact on the axon at many levels.  We have not studied dendrites in 
the present studies, but minor processes become dendrites at a later stage [12], and hence the role 
of fidgetin in determining the number of minor processes could become a major factor in the 
complexity of the dendritic arbor as well. 
Spastin and katanin preferentially sever microtubules in their stable domains [129].  A break in an 
axonal microtubule`s stable domain will create two new microtubules, each with a stable domain 
that will ensure that it does not completely depolymerize [130].  Katanin and spastin are important 
for increasing the number of microtubules in the axon and also for supplying the axon with 
microtubules that are sufficiently short so that they can undergo rapid transport events [145].  For 
these reasons, depletion of katanin or spastin is deleterious to axonal growth, while their mild 
overexpression can increase axonal growth and branching [104, 128, 129].  Compared to katanin 
and spastin , vertebrate fidgetin appears to be an unusual microtubule-severing protein. When over-
expressed in cells, vertebrate fidgetin does not create obviously greater numbers of short 
microtubules in neurons or other cell types we have studied.  We suspect that when vertebrate 
fidgetin is overexpressed, an elevation in the severing of labile domains of microtubules occurs, 
but is not obvious unless the cell is in aphase of growth, such as building an axon, wherein labile 
domains expand rather than maintain a certain length.  In the latter instance, over-expressed fidgetin 
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would tamp back the growth of labile domains such that fewer processes would form and the axon 
would grow more slowly, and this is exactly what we observed. 
While katanin and spastin activity is important for generating new microtubules to underlie axonal 
growth [118], their activity could also prune back the levels of stable microtubule mass [104].  This 
is presumably why inhibition of any of the severing proteins in Drosophila results in a greater 
number of axonal branches and synapses [122, 136].  Inhibition of vertebrate fidgetin might well 
also result in overgrown axons with more synapses, not because of abnormal microtubule 
stabilization, but rather because of uncontrolled expansion of the labile domains of microtubules 
without their normal paring back process.  However, while these phenotypes may have 
morphological similarities, the underlying microtubule arrays would be very different in terms of 
their composition and stability properties.  Recently it was discovered that the third most commonly 
mutated gene in autism is katanin-like2, a protein closely related to katanin  [202, 203].  If the 
mutations in this protein are causative of autism, the mechanism may be a result of too many 
synapses resulting from insufficient severing of microtubules either in their stable or labile 
domains.  Future anatomical studies on the brain of the fidgetin knockout mice as well as future 
studies on patients with autism or animal models with katanin-like-2 mutations will be of enormous 
interest.  We suspect that a more thorough understanding of the microtubule-severing proteins 
within humans will be instrumental to a better understanding of certain developmental disorders 
such as autism. 
Depression of fidgetin levels and boosting the overall dynamic microtubule mass could be 
beneficial also for another class of clinical applications such as degeneration of CNS neurons. A 
growing number of work indicates the tight correlation between microtubule alterations and 
neuronal degeneration caused either by  external insults (traumatic such as spinal cord injury or 
brain injury [204-207] ) or internal (such as hereditary neurodegenerative diseases [208, 209]).  
Neurodegenerative diseases are often associated with a decrease in microtubule levels, which is 
believed to cause a series of pathological effects such as impairment of axonal transport, extreme 
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reduction of dendritic spines and aberrant mis-localization of organelles especially at the 
mitochondria level [209, 210]. All these alterations will ultimately cause the premature death or 
loss of functionality of neurons. A good example is amyotrophic lateral sclerosis (ALS) , in which 
the expression of mutated SOD is related with an increase of Reactive Oxygen species (ROS) of a 
NO radical [211].  Liberation of such high reactive species hits particularly sensitive targets such 
as tubulin, which in the nitrosylated form, has a dramatic change on its polymerization rate causing 
an overall impoverishment of microtubule level in the cell. The pathological nitrosylation  has also 
a drastic consequence in the capability of Dynein to bind tubulin and consequently to correctly 
dock on to microtubules [212]. It is believed that the convergence of those two events, the reduced 
microtubule mass, indispensable for axonal transport, and reduced binding on molecular motor 
proteins could greatly contribute to the detrimental effect of mutated SOD in ALS [211]. 
Even more interestingly, in Alzheimer disease and other related cognitive dysfunctiond such as 
Tauopathy, the altered tau protein functions through a not-yet-defined mechanism (gain/loss of 
function), resulting, again, in a net loss of microtubules [213, 214]. This microtubules loss leads to 
consequential alteration of intracellular transport in the axonal compartment, and a drastic 
diminution of synaptic spines in the dendritic component [214, 215]. 
Therefore, it appears that a common denominator for many (if not all) neurodegenerative diseases 
is the loss of microtubule architecture, and regulation in neurons [209-211]. This aspect, especially 
in the last decade, has become an object of intense attention to the scientific community due to the 
possible translational aspect. In several clinical treatments, especially for anti-cancer therapy, the 
use of microtubule-targeting drugs, such as taxol that could change the dynamic profile of 
microtubule, becomes a very common and very well characterized clinical treatment [216].  
However, the clinical potential of this class of drugs has recently been extended to the neuroscience 
field. In particular, CNS permeable derivatives of taxol seem to be particularly promising for the 
treatment of several neuropathological conditions [217]. The reasons are various: first for the 
potential wide range of applications of these drugs in different neurological diseases. Indeed, very 
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different neurological pathologies, from CNS injury to neurodegeneration, are commonly 
characterized by a selective loss of microtubules. The use of a taxol derivative could collectively 
correct all these diverse conditions independently from their nature [217-219]. Another advantage 
is the safety profile of these drugs: their extensive use in oncological applications allows a thorough 
characterization under the pharmacokinetic and toxicological profile, making this drug safer for 
clinical purposes [220]. 
 Because of this, during a relatively short amount of time, a large number of effort has been focused 
on testing the putative beneficial effect of microtubule-stabilizing agents (taxol and derivatives) to 
contrast the pathological loss of microtubules in degenerating neurons. The use of this approach 
has brought several promising results, Zhang in 2005 demonstrated the beneficial effect of 
epothilone D, a CNS permeable form of taxol, under the histological (protein deposits), behavioral 
(motor improvement) and cellular (axonal transport) aspect [221]. Few years later Sengottuvel 
observed some degree of functional recovery and nerve regeneration in spinal cord injured rats 
[222, 223]. However, the discontinuation of clinical trials for treatment of mild Alzheimer patients 
(ClinicalTrials.gov Identifier: NCT01492374) could suggest more than just a problem of the 
pharmacokinetics of this drug. A note of concern has already been mentioned in the past by our lab 
regarding the balance of risk over benefit of this therapeutic approach [16]. Taxol and related drugs 
decrease the depolymerization rate of microtubules, a process that could counteract the pathological 
loss of microtubules. However, the functionality of microtubule related processes depend upon the 
contemporary presence of dynamic and stable microtubules at the same time. Although the increase 
of microtubule mass would compensate for the pathological reduction, the taxol treatment would 
cause a dangerous conversion of a large  part of the dynamic domains in stable domains, that is not 
compatible with many important neurological processes. An example is EB3: this protein is a plus 
end tip binding protein that is associated with the most extreme tip of the dynamic domain of 
microtubules [224]. The dramatic reduction of dynamic microtubules causes a dose-dependent 
ablation of EB3 protein bound to the plus tip of microtubules. Considering that the presence of 
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EB3-microtubule complex is absolutely required for normal functioning of dendritic spine, the 
dramatic reduction of these elements via taxol would preserve the neuronal cytoskeleton, but would 
not allow the expression of important functions such as spine re-arrangement [225].  
Another important process vital for the proper neuronal functioning and that can be severely 
changed by taxol treatment is the axonal transport [226]. As already mentioned, molecular motor 
proteins responsible for intracellular transport recognize the microtubule substrate in virtue of 
PTMs, such as acetylation. Several reports indicate that taxol treatment causes a substantial increase 
of acetylation [227]. This indirect effect could have several consequences on microtubule related 
transport for two reasons: one because the change on PTMs could affect the propensity of the 
molecular motor protein to transport cargo along microtubules; and the second because PTMs can 
change the affinity for MAPs to bind and eventually protect / depolymerize the microtubule. An 
example is the relation between acetylated tubulin, tau and katanin. Increase of acetylation would 
cause a reduction of affinity for tau to bind microtubules, making it more accessible to katanin, 
which has a preference for acetylated microtubule causing a potential aberrant severing and 
impairing the delicate intracellular transport [119].  
In our work with Fidgetin, we speculate that we could use another translational strategy to 
compensate the loss of microtubule mass occurring in these diseases, without passing through the 
concerns that carries the taxol treatment. The hypothetical ablation of fidgetin in a pathological 
scenario, trough for example the use of locally delivered stabilized siRNA (e.g. intrathecal / 
intraventricular injection [226]) or by the use of CRISPR technology would increase the overall 
dynamic microtubule  mass [228]. This would eventually restore all the fundamental neuroplastic 
events that are affected in the CNS pathology abovementioned. 
The importance of microtubules in neurophysiology, on the other hand, can automatically bias the 
interpretation of the patho-physiological mechanism in CNS. In this dissertation we used hereditary 
spastic paraplegia as a valid example. As previously mentioned, the most common idea about the 
molecular mechanism underpinning the HSP pathology is the lack of sufficient severing caused by 
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spastin. This conjecture known as “Loss of function” hypothesis arises from three fundamental 
reasons: A) The transmission of the disease is autosomal dominant, meaning that all the HSP 
patients are heterozygote, and consequentially producing at most  50% of WT spastin [121].   
This reduction is considered the chief pathological cause by the loss of function hypothesis, which 
could potentially induce the selective degeneration of particularly sensitive neuronal districts such 
as motor cortico-spinal neurons.  
B) The great majority of the missense mutation (hot-spot) is on the catalytic site, causing  enzyme 
inactivation through a dominant negative mechanism in most of the cases. [121, 229]. According 
to this mechanism, mutated spastin, once incorporated in the spastin hetero-hexamer (WT + 
mutated spastin), will cause the complete inactivation of the entire complex [144, 230]. 
 C) HSP can be caused by deletion of the SPAST gene, indicating that the reduced severing activity 
either by functional inactivation (as described in point 2) or the physical absence (by deletion 
described in point 3) resulting in the pathological degeneration of the CST [172]. However this 
hypothetical scenario cannot explain some important inconsistencies of the disease.  
The first is the age of onset: considering that SPG4-HSP is a typical disease with adult age onset 
[231], it is hard to explain how the lack of microtubule severing, can affect only the adult CNS 
meanwhile no effect can be observed during neurodevelopment, where paradoxically the 
requirement of plasticity is much higher. 
 The second incongruity is the explanation of the specificity of the HSP to the CST. Under the loss 
of function idea, the cortical neurons of the CST degenerate because the lack of severing is 
particularly detrimental to neurons with extremely long axons, such as the first order neurons from 
this circuit. However the relation between axon length and microtubule severing should be even 
more valid in other long nerves in our body such sciatic nerve, where length easily exceeds those 
from the motor CST neurons.  
Third, the loss of function hypothesis cannot give a good explanation of the lack of correlation 
between the phenotype of patients having a deletion on SPAST gene from the one having a single 
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nucleotide mutation (missense). Indeed under the dominant negative mechanism, the severing 
activity of mutated spastin would cause a higher degree of endogenous spastin inhibition compared 
to the activity inhibited by deletions. Patients bearing deletion mutations have a roughly 50% 
decrease of the WT spastin protein, with an obvious decrease of the overall severing activity by 
half. On the other hand, in missense mutated spastin less than 50% of spastin is expected to actually 
work, considering that the introduction of even a single subunit in the entire hexamer would result 
in a total loss of the severing activity. Because of this, if the insufficient severing is the ultimate 
cause of the HSP pathology, patients affected by missense SPAST mutation would have a much 
more severe phenotype than people affected by a deletion. However no correlation can be made 
between the type of mutation and the severity of the pathology [231].  
In our work we propose that the mutated spastin could act in the context of HSP through a different 
mechanism of action: through a gain of function mechanism. The idea behind the gain of function 
hypothesis is that the disease is not caused merely by the lack of microtubule severing, but also by 
an additional de novo biological activity, or by a misregulated endogenous (different from severing) 
activity.  
This idea is not absolutely new, conversely, several pieces of work suggest that the gain of function 
mechanism could act in the context of several neurodegenerative diseases, including proteins such 
as synuclein [232], tau [233] and huntingtin [232]. The central concept of this hypothesis is that the 
altered structure caused by mutation could form (or deregulate) interactive surfaces on the mutated 
protein, inducing the aberrant activations of a pathological pathway that should not be activated. 
The newly acquired biological function results in a disturbed equilibrium of the homeostatic 
balance within the neuronal cell, causing the progressive degeneration. The importance of 
understanding which of the two separate mechanisms (loss vs. gain of function) better illustrate the 
disease progression, do not have just a speculative nature, but have more importantly, a great 
translational implication. Indeed the possible existence of a gain of function mechanism would 
suggest completely different therapeutic strategies from the one indicated for a loss of function.  
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For the latter, the best therapeutic approaches would be essentially two. A direct approach, focused 
on increasing spastin microtubule- severing activity, activity apparently lost in the disease, through 
CRISPR strategy or unknown activators. A second approach is to lower microtubule stability with 
the use of microtubule destabilizing agents such as Nocodazole, in order to contrast the increased 
microtubule stability caused by the lack of severing of spastin [173].  
In the gain of function scenario proposed in this work, the translational approach would be 
completely different: it would target the gain of function effectors of mutated spastin, such as CK2. 
Over the past few years the advancement of research on CK2 has produced excellent inhibitors 
already used for clinical application [234]. One of the best drugs is CX-4945 used for hematological 
malignancies, which toxicological and pharmacokinetic profiles have already been extensively 
described [235, 236]. Interestingly, in a very recent paper, this inhibitor has demonstrated to 
efficiently cross the blood brain barrier and be capable to reduce several aberrantly phosphorylation 
substrates of CK2 and closely related kinases, such as Tau in mouse AD model after oral 
administration [197].  
The possibility to use a CK2-blocking strategy, with the administration of very low doses of 
systematically administered / locally delivered drugs, opens up a completely new avenue for the 
treatment of HSP. Even more importantly, it can possibly give  the pharmacology field a completely 
new category of anti-neurodegenerative drugs, targeting no longer the aggregation ofdeposits, but 
rather the possible biochemical alterations that the misfolded proteins would cause at the signaling 
level.  
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